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Abstract  
 
Ovarian cancer is the fifth most common cancer among women, with a great demand 
for the development of diagnostics towards improved performance, shorter turnaround time 
and lower costs. Lipids represent an important class of biomolecules with a unique but 
nevertheless poorly understood role in cancer pathophysiology. DESI-MSI (Desorption 
electrospray ionization mass spectrometric imaging) is an emerging mass spectrometric 
technique with great potential in cancer diagnostics and prognostics, giving spatially resolved 
profiling information. These techniques provide information on the metabolic and lipidomic 
profile of tissues, giving insight into tumour systems biochemistry.  
The hypothesis of this study is that spatially resolved molecular phenotypes (i.e. 
distribution of lipid species in the tissue) measured by modern mass spectrometry technologies 
can capture systems biochemistry in different subtypes of ovarian cancer. To validate this 
hypothesis epithelial ovarian carcinoma samples (with a total of 112 samples including 
different epithelial ovarian carcinomas and healthy ovary) were analysed by DESI - MSI. With 
the histologically resolved lipidomic information given by DESI, multivariate statistical 
analysis was performed. The analysis of the spectral content revealed changes in the relative 
abundance of different classes of phospholipids as well as changes inside the class related to 
the fatty acid composition of these lipid species.  
A semi-targeted LC-MS method for phospholipids and sphingolipids was developed to 
be used for the analysis of the ovarian sample set in order to refine the findings of the DESI-
MSI study. The DESI stage was also coupled with a triple quadrupole to optimize a targeted 
analysis with spatial information.  
In conclusion DESI MS was successfully used to analyse the lipidome of epithelial 
ovarian carcinoma. This analysis allowed us to better characterise the metabolic variations 
within and between histological groups and possibly the beginning of a new tool for a more 
precise epithelial ovarian cancer diagnosis and prognosis.  
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1. Introduction 
 
1.1. Cancer  
 
Cancer causes a vast number of mortalities worldwide each year, which makes it one 
of the most devastating human diseases. There are more than 200 types of cancer, each with 
different causes, symptoms and treatments, making it extremely complex and one of the biggest 
problems worldwide. This complexity is due to cancer being a highly heterogeneous collection 
of different diseases with different risk factors, clinical presentations, pathological features, 
responses to therapy and outcomes [2]. Despite significant advances in diagnosis and treatment 
of cancer, several major unresolved clinical and scientific issues still remain. These are related 
to prevention, diagnosis, tumour progression, recurrence, and treatment.  
In a simplified scenario of their physiology, cancer cells are not capable of growing and 
multiplying in an orderly and controlled fashion. They start to divide and multiply very quickly 
and thus randomly suffering imbalances in tissue formation which subsequently results in a 
tumour (described previously in numerous reviews [3, 4]). Consequently, the cell metabolism 
undergoes a metabolic reprogramming, which increases the rate of cell reactions such as for 
the production of (amongst others) adenosine triphosphate (ATP), lipids, nucleotides, and 
amino acids. These remarkable changes in the biological function of cancer cells are the direct 
consequence of the enormous variability and instability of the genomes which arise through 
the translation of multiple deoxyribonucleic acid (DNA) mutations [4].  
The first and the most remarkable metabolic alteration in cancer described is the 
increase of glycolysis, which is followed by lactic acid fermentation in the cytosol. This process 
occurs even under aerobic conditions (known as the Warburg effect) [5], causing a fundamental 
difference in the metabolism of cancer cells compared with normal cells, which rely 
predominantly on the tricarboxylic acid (TCA) cycle in the mitochondria for their energy 
supply. 
Hanahan et al [4, 6] described and revised a number of defining characteristics or 
“hallmarks” of cancer cells, detailing multiple and complementary capabilities which enable 
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tumour growth, survival and metastatic dissemination [4]. These hallmarks include sustaining 
proliferative signalling, evading growth suppressors, enabling replicative immortality, resisting 
cell death, inducing angiogenesis and activating invasion and metastasis (Figure 1.1.1).  
 
 
 
Figure 1.1.1. Hallmarks of cancer and the therapeutic targeting, adapted from [4].  
 
 
The chronic rate of proliferation which cancer cells are able to sustain is achieved by 
deregulating the normal homeostasis of the cell growth and division cycle, which is of the 
foundation of normal cell architecture and function. The enabling signals are carried in large 
part by growth factors which bind cell-surface receptors, typically containing intracellular 
tyrosine kinase domains. In addition, cancer cells must also avoid powerful endogenous 
signalling pathways which negatively regulate cell proliferation; many of these pathways 
depend on the actions of tumour suppressor genes. Normal cell lineages are able to undergo 
only a limited number of successive cell growth-and-division cycles. This limitation has been 
linked with two distinct barriers to proliferation: senescence, a typically irreversible entrance 
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into a non-proliferative but viable state, and crisis, which involves cell death. Multiple lines of 
evidence indicate that telomeres protecting the ends of chromosomes play a central role in the 
capability for unlimited proliferation [7, 8].  
Besides proliferation, cancer cells need to avoid programmed cell death by apoptosis, 
which serves as a natural barrier to cancer development [9, 10]. Elucidation of the signalling 
circuitry governing the apoptotic program has revealed how apoptosis is triggered in response 
to various physiologic stresses that cancer cells experience during the course of tumorigenesis 
or as a result of anticancer therapy [11].  
Due to the fact that apoptosis causes minimal inflammation and damage to the tissue, 
apoptotic cell death-based therapy has been the centre of attraction for the development of 
anticancer drugs. Increased understanding of the molecular pathways underlying apoptosis has 
enabled scientists to develop drugs that act either by blocking the action of antiapoptotic 
proteins, or by halting, hampering or interference with the transcription of RNA, demonstrating 
a robust potential for use in cancer therapeutics [12].  
To adequately respond to this quick growth and proliferation, tumours require 
sustenance in the form of nutrients and oxygen, as well as an ability to rapidly evacuate 
metabolic wastes and carbon dioxide. During tumour progression, an ‘‘angiogenic switch’’ is 
almost always activated and remains switched on, causing normally quiescent vasculature to 
continually sprout new vessels which then help to sustain expanding neoplastic growths [13].  
E-cadherin, a key cell-to-cell adhesion molecule, is characterized to be altered in cancer 
cells. E-cadherin is responsible for the assembly of epithelial cell sheets, and to maintain their 
quiescence. Increased expression of E-cadherin was well established as an antagonist of 
invasion and metastasis, whereas reduction of its expression was known to potentiate these 
phenotypes. The frequently observed downregulation and occasional mutational inactivation 
of E-cadherin in human carcinomas provided strong support for its role as a key suppressor of 
this hallmark capability [14]. 
With further research into cancer development, additional hallmarks have been added 
to the original list, including the capability of cancer cells to evade immunological destruction, 
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and the dysregulation and adjustment of cancer cells metabolism to effectively support 
proliferation [4].  
 
1.1.1. Ovarian cancer 
 
Women diagnosed with early-stage of ovarian cancer have a 5-year survival rate of 
approximately 80–90% but this decreases dramatically to 20–30% in late-stage diagnoses [15]. 
More than 80% of early-stage cancer patients exhibit related symptoms; however, these 
symptoms are shared with many more common gastrointestinal, genitourinary and 
gynaecological conditions, and have not yet proved useful for early diagnosis. For these reasons 
ovarian cancer has been also termed as the ‘silent killer’, and research for an early diagnosis is 
therefore particularly critical for this type of cancer.  
Approximately 80-90% of ovarian malignancies are epithelial in origin [16]. Based on 
histopathology and molecular genetic alterations, epithelial ovarian carcinoma (EOC) can be 
divided into five main types (Figure 1.1.2): high-grade serous (70%), endometrioid (10%), 
clear-cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%) [17, 18]. These 
types are further subdivided into benign, borderline (intermediate), and malignant (carcinoma), 
depending upon the degree of cell proliferation and nuclear atypia, and the presence or absence 
of stromal invasion [18].  
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Figure 1.1.2. The percentages of the different types of epithelial ovarian carcinoma (EOC), together 
with a characteristic hematoxylin and eosin stain (H&E) of each type (adapted from [19]) 
 
 
Borderline tumours show epithelial proliferation greater than benign tumours and 
variable nuclear atypia; however, in contrast to carcinomas, there is an absence of stromal 
invasion, and their prognosis is generally much better than for carcinomas. In spite of the lack 
of ovarian stromal invasion, serous borderline tumours can implant on peritoneal surfaces and, 
rarely (about 10% of peritoneal implants), can progress to low-grade serous carcinoma and 
invade the underlying tissues. 
The cellular origin of EOC and the development of its carcinogenesis have been long 
debated. Originally, ovarian cancer was described as originating in the ovarian surface 
epithelium (mesothelium), which invaginates into the underlying stroma. This results in 
inclusion cysts within the tissue which eventually undergo malignant transformation, leading 
to the development of the different ovarian cancer cell types (serous, endometrioid, clear cell, 
mucinous). With advances in molecular biology and genetics, EOC were proposed to be 
derived from müllerian type-tissue, and are therefore müllerian-derived epithelial tissue (such 
as epithelia from the cervix, endometrium, and fallopian tubes). Two notable characteristics 
discovered which support this theory are expression of PAX8 (Paired box gene 8) [20], a 
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Müllerian tissue marker, and the similarity of gene profiles of fallopian tube epithelium as 
compared with those of  EOC [19].  
Another interesting aspect in pathology which has not been elucidated completely is 
the histogenesis of endometriosis and endometriosis-associated ovarian cancer [21]. A number 
of studies to date have suggested that clear cell and endometrioid type carcinomas are 
frequently associated with endometriosis [22]. These two types of EOC are driven from 
different tissue types, and consequently are different types of endometriosis. This observation 
is supported by the expression of the hepatocyte nuclear factor (HNF)-1 β, where endometrioid 
adenocarcinoma arises from the HNF-1β-negative epithelial cells while clear cell carcinoma 
arises from HNF-1β-positive epithelial cells of endometriosis [21, 23]. 
Although many questions still remain unanswered about this paradigm of EOC 
pathogenesis, advances in research have opened a vast number of opportunities to better 
understand this carcinogenesis.  
 
1.2. Lipids 
 
Lipids represent an important class of molecules, which play a broad range of roles in 
cellular processes, with this ability largely attributed to their dynamic and interactive nature. 
They are not only responsible for the membrane structure and energy storage, but also have 
vital regulatory and signalling functions. Due to their diversity and combinatorial structures, 
there are already over 37,500 lipids described in the LIPID MAPS Structure Database [24].  
The lipid classification system which is currently most frequently referenced was 
proposed in 2005 by Fahy and co-workers [25], and updated in 2009 to encompass lipid 
structures from non-mammalian sources such as plants, bacteria, and fungi [26]. As a result, 
there are eight lipid categories, which cover both eukaryotic and prokaryotic lipids: fatty acyls, 
glycerolipids, glycerophospholipids or phospholipids, sphingolipids, sterol lipids, prenol 
lipids, saccharolipids, and polyketides.  
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The most common lipid classes which play important roles in membrane structure and 
energy storage are glycerophospholipids, sphingolipids (Figure 1.2.1), sterols and triglycerides. 
Another classification system used to categorise the most abundant lipids references the 
different charge properties of lipids: anionic (phosphatidic acid (PA), phosphatidylglycerol 
(PG), phosphatidylinositol (PI), phosphatidylserine (PS), cardiolipin (CL)), weakly anionic 
(ceramide (Cer), phosphatidylethanolamine (PE)) and ‘neutral’ lipids (mono, di, 
triacylglycerol, cholesterol esters, phosphatidylcholine (PC), sphingomyelin (SM)) [27]. 
 
 
 
Figure 1.2.1. Different classes of phospholipids and sphingolipids 
 
Underlining the importance of lipids in cellular structure and function, 5% of eukaryotic 
cell genes are directly involved in the cellular lipid metabolism. The lipidome, which is often 
considered as a sub-fraction of the metabolome, in fact contributes around 70% of entries in 
the Human Metabolome Database [28].  
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1.2.1. Lipid synthesis, function and location in the cell 
 
The major structural lipids in eukaryotic membranes are the glycerophospholipids: PC, 
PE, PS, PI and PA. Their hydrophobic portion is a diacylglycerol (DAG), which contains 
saturated or cis-unsaturated fatty acyl chains of varying lengths (Figure 1.2.1). Also, highly 
abundant in the cell membrane are sphingolipids and cholesterol, which constitute the main 
lipids in the membrane domains called lipid rafts [29, 30]. PC and PI classes are the major 
eukaryotic glycerophospholipids, with PCs constituting more than 50% of the phospholipids 
present in most eukaryotic membranes [31].  
The main cellular site of lipid synthesis is the endoplasmic reticulum (ER), where most 
of the structural phospholipids (as PC, PE, PS and PI) and ceramides are synthetized in the 
cytosolic surface. Cholesterol is also synthesised in the ER, and is rapidly transported to other 
organelles. Mitochondria can produce PA, PE, PG and CL, with the latter two classes generally 
confined specifically to this organelle. The Golgi is also responsible for the synthesis of 
different sphingolipids, such as SMs and various glycosphingolipids, all of which are primarily 
destined for export to the plasma membrane [31]. Sphingolipids are synthesised on the luminal 
surface of the Golgi membrane, and are found on the outside of the plasma membrane, whereas 
the aminophospholipids PS and PE are actively concentrated in the cytosolic leaflet [32]. 
Lipids can be characterized by their three main functions: energy storage, as structural 
moieties, and as signalling molecules. Triacylglycerol and steryl lipids are mainly used for 
energy storage in their characteristic lipid droplets. These lipid droplet reservoirs work as 
efficient intracellular storage of caloric reserves, and provide a dynamic and readily mobilised 
supply of fatty acids and sterol components needed for membrane biogenesis [33]. Their 
nonpolar properties, and so a nearly anhydrous form, make them a much more efficient than 
proteins and carbohydrates, with a polar signature.  
One of the most important lipid roles (if not the most important) is in the formation and 
maintenance of the matrix of cellular membranes, which are dominated by polar lipids, and 
consist of a hydrophobic and hydrophilic portion. Singer and Nicolson were the first to propose 
that membranes were formed by a fluid bilayer in which proteins and lipids could move freely 
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– the fluid mosaic model – contributing greatly to our concept of a cell membrane [34]. The 
physical driver of the formation of membranes is conferred by their amphipathic nature, 
consisting of both hydrophobic structures and their self-association propensity in aqueous 
media, as well as the tendency of the hydrophilic moieties to interact with aqueous 
environments and with each other. These principles allow cells to effectively segregate their 
internal constituents from the external environment, as well as the production of discrete 
intracellular organelles. Besides these important barrier functions, membrane lipids are 
essential for the budding, tubulation, fission and fusion characteristics that are necessary for 
both cell division and intracellular membrane trafficking.   
 
 
Figure 1.2.2. Main locations of phospholipid synthesis together with the lipid composition of the 
different cell organelles. The lipid composition expressed in percentages in the graphs represent the 
total phospholipids in mammals (in blue) and yeast (light blue) (from [31]).  
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All lipid functions (membrane dynamics, energy homeostasis, and molecular 
machinery regulation) are vital for the most critical aspects of cellular function, such as 
proliferation, inflammation, immunity, apoptosis and invasion. An imbalance in lipid 
homeostasis and metabolism is particularly characteristic of cancer cell physiology, where all 
cell efforts converges to lipid synthesis in order to build new cell membranes and to participate 
in signalling cascades [35].  
 
1.2.2. Lipids and cancer  
 
Given the tight homeostatic control of lipid metabolism, and its enormous relevance to 
cellular structure and bioenergetics, it is evident that alterations in lipid metabolism necessarily 
play important roles in the different pathogenic mechanisms of cancer [36].  
The first adaptive change cancer cells demonstrate is the increase and deregulation of 
glucose uptake, the well-known “Warburg effect” [5]. Linked to this alteration, cancer cells 
also rely on glutamine consumption, which provides the carbon and amino-nitrogen needed for 
amino-acid, nucleotide and lipid biosynthesis [37, 38], altering carbon metabolism and 
glycolysis which contribute to anabolic processes. Figure 1.2.3 demonstrates the main cellular 
metabolic pathways altered in cancer directly linked to lipid metabolism.  
Despite being far from completely understood, the need of an excess of structural lipids 
and generation of energy demonstrate how alterations in the lipid metabolism in cancer cells 
are important and how crucial it is to understand the role of these molecules.  
 
35 
 
 
 
Phospholipid membranes  
 
Important changes in lipid composition and abundance, particularly in fatty acid chain 
saturation and head group proportions (which impact membrane lipid molecular shape and 
conformation), can have dramatic effects on membrane fluidity and protein dynamics. For 
example, an increase in saturated phospholipids in the cell membrane markedly alters signal 
transduction, protects cancer cells from oxidative damage such as lipid peroxidation and 
potentially inhibits the uptake of chemotherapeutic drugs [39]. This membrane lipid saturation, 
a feature shared by all lipogenic tumours, correlated with high tumour grade and poorer overall 
survival [40, 41].  
Figure 1.2.3. The map of the main altered lipid metabolic pathways in cancer cells. Lipid metabolic network (blue) 
includes import/export and catabolic pathways as well as de novo synthesis pathways, such as lipogenesis and 
cholesterol synthesis (adapted from [1]).  
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The most abundant phospholipids in the membrane, PCs, as well as PEs were presented 
in high levels in breast cancer cell lines [42]. Alterations in choline metabolism, including an 
increased expression of choline kinase expression and activity as well as higher rate of choline 
transport, contribute to the increase of PC levels. Choline kinase is an enzyme responsible for 
PC formation from choline, and its overexpression was also detected in several human cell 
lines of breast cancer [42, 43].  
 
Membrane domains  
 
Cell membranes also contain different microdomains important to the membrane 
integrity and stability. A notable example is lipid rafts, membrane domains which are rich in 
cholesterol and SM, and essential not only for membrane protein dynamics, but also for cell 
survival and the execution of programmed cell death. The proteins sequestered into membrane 
rafts can turn these domains into functional signal transduction structures in which are 
necessary for endocytosis, cell death regulation, and other events relevant to cancer therapy 
[44].  
Anchored lipid raft proteins such as protein kinase B (also known as Akt) have been 
extensively investigated in cancer cells [1]. The aberrant activation of Akt contributes to 
tumour development and invasiveness and correlates with increased lipid rafts in cancer cells 
[45, 46]. Lipid raft disruption inhibits Akt activation, which then reduces tumour cell 
proliferation cancer cell migration [47].  
There is evidence of a subset of lipid raft domains that is enriched in ceramides and 
SM, and functionally appears to generally promote apoptosis. These ceramide-rich domains 
help amplify weak primary signals; for example, for death receptors which transmit a strong 
signal to the cell and thus trigger apoptosis. When ceramide in these domains is replaced by 
cholesterol, the domains become involved in normal cell signalling. The deregulation of lipid 
rafts which are rich in cholesterol promotes cell transformation and tumour progression [48, 
49]. The cholesterol content of  these lipid rafts are enhanced in the cell membranes during the 
development of multiple cancer cell types [50], as well as in the membranes of exosomes 
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released from tumours [51, 52]. In pancreatic tumours, for example, the lipid profile reveals a 
high dependence of cancer progression on cholesterol content and identifies exogenous 
cholesterol uptake as a major pathway mediating tumour growth [53]. The excess of this 
cholesterol in cancer cells is stored in lipid droplets, and high number of lipid droplets with 
stored cholesteryl ester content in tumours is also a hallmark of cancer aggressiveness [54, 55].  
 
Signalling lipids  
 
Ceramides and sphingosines also possess pro-apoptotic and anti-proliferative activities 
when converted into ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) 
respectively [56]. High levels of S1P promote proliferation and survival in cancer cells. S1P 
receptors (S1PR) were recently discovered and are considered a requirement for tumour 
angiogenesis [57, 58]. The different sphingolipid metabolites are also actively involved in 
glucose uptake, being able to inhibit (sphingosine) or activate (S1P) it. Linked to this, 
sphingosine can also inhibit, and S1P activate, insulin signalling pathways and mediate the 
expression of Akt [59].  
PIs, their metabolites such as PA, DAG and PI derivatives for instance 
phosphatidylinositol phosphates (PIPs), are also very important contributors to cellular 
signalling cascades, which activate proliferation, maintain survival and promote migration [60-
62]. For example, phosphatidylinositol 3 kinase (PI3K) phosphorylates and controls the 
conversion of phosphatidylinositol 4,5 bisphosphate (PIP2) resulting in phosphatidylinositol 
3,4,5 trisphosphate (PIP3), which acts as a secondary messenger and controls cell growth, 
survival, proliferation, motility and morphology [63]. The protein phosphatase and tensin 
homologue (PTEN) also uses PIP3 as its main target but has the opposite function of PI3K 
[64]. Aberrant activation of the inositide signalling pathway by overexpression of PI3Ks and 
inactivation by genetic and epigenetic mutations of the PTEN gene results in accumulation of 
PIP3. This defect plays a crucial role in the development of different tumours, such as in the 
oncogenic mechanism in gastric cancer and colorectal cancer, and can lead to a cytoskeleton 
rearrangement that is subsequently stimulated, increasing migration and metastasis. 
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PA has also shown to be critical and essential for key signalling molecules that regulate 
cell cycle progression and survival, as mTOR (mammalian-mechanistic target of rapamycin) 
activity. To better elucidate, mTOR activity is required for progression from G1 into S-phase, 
indicating that PA, via input from mTOR, is required for cell cycle progression [65, 66]. PA 
was first demonstrated to be involved in the regulation of mTOR in 2001 [65], showing that 
exogenously added PA stimulated the activation of the mTOR substrate S6 kinase and 
phosphorylation of another mTOR substrate ‘eukaryotic initiation factor 4E binding protein-1’ 
(4E-BP1) in human embryonic kidney (HEK293) cells. Due to its link to survival signals, 
mTOR has been implicated in several human cancers [67]. PA has a direct role in stimulating 
mTOR expression by competing with the action of rapamycin, making it a potential target for 
therapy.  
Consistent with this emerging role for PA in regulating cell proliferation, and either the 
elevated expression or activity of enzymes that generate PA is commonly observed in human 
cancer, most notably phospholipase D (PLD) [67], which is elevated especially in K-Ras-
driven cancers [68, 69]. 
 
Fatty acids  
 
Changes in the lipid pattern of the metabolic profile can occur not only between classes 
but also within a single class. For example, in breast cancer cell lines, a shift between different 
molecular species of phospholipids with different fatty acids is observed, with higher evidence 
in the PI class  [70, 71].  
Another hallmark of the transformed phenotype, which has received less attention but 
is increasingly being recognised, is an increase in de novo fatty acid synthesis [72, 73]. This 
metabolic shift is functionally related to the glycolytic pathway, and supporting evidence for 
this change includes increases in the expression of fatty acid synthetase (FASN), a phenomenon 
which is well-described in the literature [74, 75]. Acetyl-CoA and subsequently citrate are 
influenced by the increase of ATP citrate lyase (ACLY) to augment de novo fatty acid synthesis 
and give a quick response to the cell growth and proliferation. 
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On the other hand, cancer activated pathways, such as the PI3K/Akt signalling system, 
have been shown to suppress expression of β-oxidation of fatty acids during anabolic growth 
[76], diverting the fatty acids away from degradation in the TCA cycle, which preserves them 
for synthesis of more complex lipids. Thus, the shift from lipid uptake to de novo lipogenesis 
[75, 77] has consequences on the fatty acid and lipid composition of the entire cell.  
 
 
1.2.2.1. Lipid metabolism and ovarian cancer  
 
Extensive reviews have described several metabolomics / lipidomic approaches in 
ovarian cancer [78-81]. Most of these mass spectrometry-based studies (with comprehensive 
extraction and chromatographic analysis with gas chromatography mass spectrometry (GC-
MS) or liquid chromatography mass spectrometry (LC-MS)) were performed in a variety of 
matrices, including serum/plasma, urine, cyst fluid, tissue and ascetic fluid [82-85].  
The alterations described in the lipid metabolism include enhanced fatty acid β-
oxidation, manifesting as high levels of carnitine proteins in the serum and tissue of patients 
with EOC [86, 87]. Consistent with this enhanced fatty acid oxidation, abnormal levels of 
glycerolipids, phospholipids, sphingolipids and altered concentrations of long chain fatty acid 
(palmitate, oleate, and myristate) as derivatives were additional common findings of the studies 
reviewed [88-90]. Fan et al. [91] subsequently identified eight candidate biomarkers for the 
diagnosis of EOC, mostly ceramides and lysophospholipids. The validation results of these 
combined markers in an independent cohort was evaluated with a sensitivity of 92% and a 
specificity of 89% for detecting EOC. Hou et al. [92] also undertook a study of plasma lipid 
profiles by ultra-performance liquid chromatography - mass spectrometry (UPLC- MS). They 
observed 52 potential lipid metabolites crucial for EOC diagnosis and staging, which were 
classified as phospholipids (i.e., PCs, PEs, PGs, and lysophosphatidylcholine (LPC)), 
sphingolipids (i.e., SM, Cer, Glc series, and Globo series) and glyceroglycolipids (i.e., 
monoacylglycerol (MG) and DAG). The study demonstrated how the lipidome could be used 
to discriminate EOC from benign, and illustrated the potential of the phospholipid profile for 
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characterisation and diagnosis of ovarian cancer [92]. Lysophosphatidic acid (LPA) 
demonstrated to be another interesting class described as consistently increased in preoperative 
cancer patients in Stuphen et al. and Shan et al. [82, 83].  
Directly linked to the Akt/PI3K/mTOR pathway, various genetic alterations have been 
found in ovarian cancer [93]. As stated previously, this pathway is directed linked to the 
phospholipid metabolism and phosphatidic acid pathways. Despite far from being completely 
understood, these lipid pathways have demonstrated to be vital in cancer biochemistry [64].  
 
Despite lipidomics being an emerging field, which focuses on building a comprehensive 
identification of all individual lipid species and their interactions, the majority of potential lipid 
biomarkers are rarely used in cancer diagnosis. Furthermore, the precise physiological 
functions of this class in cancer metabolism are far from being understood, particularly at the 
molecular level. Thus, it is very important to further understand the role of these altered lipids 
in lipid metabolism and also their distribution during cancer progression. 
 
 
1.3. Lipidomics and Mass Spectrometry  
 
Mass spectrometry (MS) is a powerful tool, which is being increasingly employed in 
lipidomics applications, complementing thin layer chromatography (TLC) which was, until 
recently, the gold standard technique for the analysis and study of lipids. MS enables the 
detection, identification, characterisation, and quantitation of various lipid species [27, 94] and 
mass spectrometers can be coupled with a preceding inline sample separation technique, GC–
MS [95] or LC–MS [70], both of which are widely used in lipidomics. However, the workflow 
necessarily involves some sample preparation, most often an organic extraction or a simple 
protein precipitation, (depending on the sample type) [96]. For MS imaging, sample 
preparation can be much simpler, with the minimum preparation necessary being sectioning 
the tissue and mounting on appropriate surfaces for analysis, such as glass slides.  
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Figure 1.3.1. Mass spectrometry - from sample preparation to data analysis (adapted from [97]) 
 
 
1.3.1. Sample preparation and lipid extraction  
 
Multiple biological sample types have been investigated for use in lipidomics 
applications, with the most common types examined in the literature being tissue, serum, 
plasma and urine. Depending on the lipid class of interest, the composition of organic solvents 
can be adapted to optimise the efficiency of lipid extractions. The range of physicochemical 
properties of lipids must be taken into account by extraction methods: for example, the 
chemistry of phospholipid molecules generally requires the presence of a more polar solvent, 
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such as ethanol or water, followed by a secondary extraction of sample with a non-polar 
solvent, as chloroform, for a complete extraction of the less polar lipids [97].  
Perhaps the most well-known lipid extraction methods was developed in the 1950s by 
Folch [98], which used chloroform / methanol (2:1 v/v) , followed by a high volume of water 
to remove the non-lipid sample components. Bligh and Dyer later developed their method, 
which was essentially an adaptation of the Folch method [99] but specifically intended for 
tissues with high water content. The Bligh and Dyer method calculates the amount of water in 
the sample so that the final composition of chloroform / methanol / water will be 1:2:0.8 (v/v/v), 
and has the benefit of being an efficient and quick extraction method which recovers a broad 
range of lipid classes. After the addition of water and chloroform, the lipids are yielded in the 
organic phase, after a secondary washing with water and methanol to eliminate the non-lipid 
contaminants. To enhance the recovery of phospholipids, the methanol proportion can be 
increased.  
 
1.3.2. Chromatography for lipid separation  
 
The variety of chromatographic techniques currently available are powerful tools in the 
lab for the separation and identification of different compounds in a mixture. Chromatography 
takes advantage of the different affinities of analytes with the mobile phase and stationary 
phases used (such as difference in polarities, hydrophobicity and other physicochemical 
factors) to achieve separation of complex mixtures. The mixture dissolved in a liquid solvent, 
acting as a mobile phase, sweeps over a bed of particles called the stationary phase, which 
separates the analyte to be measured from other molecules in the mixture based on differential 
partitioning between the mobile and stationary phase. Molecules having a greater affinity to 
the stationary phase travel slower than the ones with lesser affinity. The separated molecules 
are then compared to known standards and identified. 
The most popular techniques of chromatography are TLC, GC, LC, the latter which 
includes high-performance liquid chromatography (HPLC) and UPLC. These techniques, 
when coupled with MS, function as a pre-separation of the complex molecular mixtures 
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facilitating further analysis and identification of different molecules. In lipid analysis, 
chromatographic separation is extremely useful to separate and isolate the numerous different 
lipid classes - which each contain species with broad ranges of physicochemical properties, a 
notable example being the phospholipid classes - in a complex biological sample. The most 
common chromatographic technique used in lipidomics is HPLC, and the more recently 
developed UPLC [100].    
HPLC was first produced and commercialised by Waters in 1969, remaining the 
predominant technology used in laboratories worldwide for over 30 years. Despite the advances 
in HPLC technology, there was a need for faster run times, to answer to the demand in high 
number of samples to the studies cohort. Different attempts were made to make the analysis 
faster, as elevated temperatures for lower viscosity. However, the use of these particle sizes 
and pressures reaches a limit where compromises are necessary, normally resolution for time. 
Decreasing the size of the particles in the column can take speed and peak capacity to new 
boundaries. Moreover, not only is there a significant gain in efficiency, but the efficiency does 
not diminish at increased flow rates or linear velocities; UPLC was introduced with improved 
chromatographic efficiency using higher pressures than HPLC [101]. 
The use of LC-MS for phospholipids and sphingolipids has increased in the last decade, 
showing the increased relevance of understanding the role of these molecules in the metabolism 
[102, 103].  
 
1.3.3. Mass Spectrometry   
 
Mass spectrometry is an analytical technique that allows the separation and detection 
of gas phase ions according to their mass / charge (m/z) value. With this technique it is possible 
to detect and identify compounds at very low concentrations in chemically complex mixtures, 
since the identification can be made from very small quantities.  
All mass spectrometers consist essentially of four basic components (Figure 1.3.2) 
[104]: the ionisation source, the vacuum system, the mass analyser and the detector. The ion 
source as its name suggests, produces the ions to be analysed and, depending on the phase of 
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the sample (solid, liquid or gas) and the efficiency of the ionisation mechanism involved, a vast 
number of ionisation techniques can be applied. The analyser gives the actual separation of 
ions according to their m/z value using a static or dynamic electromagnetic field. Many mass 
spectrometers use two or more mass analysers to perform tandem mass spectrometry (MS/MS). 
The detector will collect and characterize the ions separated previously producing a signal 
whose intensity is related to the number of ions detected. This signal is detected either by the 
charge induced or the current produced when an ion passes by or hits the surface of the detector. 
These detectors are connected to a computer that provides mass spectra recording the m/z 
corresponding to each ion and the correspondent relative abundance.  
A critical feature of these instruments is the high vacuum present that allows free 
movement of ions through the spectrometer without simultaneous reactions or changes of the 
ions, and which also enables the removal of neutrals which might otherwise impact the 
collimation of the ion beam.  
 
 
 
Figure 1.3.2. Schematic of a typical mass spectrometer  
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Ionisation sources  
 
There have been a variety of ionisation techniques developed to date, with diverse 
approaches in the formation of ions and conditions under which they are performed.  
 
Table 1.3.1. Different ion sources and their characteristics [105] 
Ion source  Symbol 
Ionising 
process 
Mass Range Compounds  
Electron impact EI 
Exposure to 
electron stream 
~1000 Da 
Thermally volatile 
and stable 
Chemical ionisation  CI 
Reagent 
gaseous ions 
~1000 Da 
Thermally volatile 
and stable 
Fast atom 
bombardment  
FAB 
Energetic atom 
beam 
7000 Da Peptides, sugars  
Secondary ion mass 
spectrometry 
SIMS 
Energetic beam 
of ions 
300-13000 Da Peptides, sugars  
Matrix-assisted laser 
desorption ionisation  
MALDI Laser beam 500,000 Da Large biomolecules  
Electrospray 
ionisation  
ESI 
High electric 
field 
~100,000 Da 
Biomolecules (from 
basic and polar to 
peptides and proteins) 
Desorption 
electrospray 
ionisation  
DESI 
Electrospray 
beam 
~100,000 Da 
Biomolecules (from 
basic and polar to 
peptides and proteins) 
 
 
The earliest ionisation technique published was electron ionisation (EI), also referred 
to as electron impact ionisation, first described by Dempster, and later improved by Bleakney 
and Nier [106, 107]. This ionisation technique can be applicable for many gas-phase molecules 
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and thermally stable but with the major disadvantage of an extensive fragmentation caused by 
the high energy applied by the electron beam and, consequently, the molecular ions are not 
always observed. To mitigate this problem, softer ionisation methods were required, giving rise 
to the development of chemical ionisation (CI). Although this technique has the advantage of 
yielding a spectrum with less fragmentation in which the parent molecular ions are present, CI 
remains predominantly suitable for volatile and thermally stable compounds.  
To overcome these limitations, fast atom bombardment (FAB) and secondary ion mass 
spectrometry (SIMS) were developed, which permitted analysis of non-volatile and thermally 
unstable samples by MS. SIMS appeared in the 1940s, initially described by Herzog [108], and 
the method produces secondary ions from the sample when its surface is irradiated with an 
energetic primary ion beam. Both FAB and liquid secondary ion mass spectrometry (LSIMS) 
techniques also rely on the analysis of secondary ions emitted when the surface is irradiated 
with a primary beam of atoms in FAB and beam of molecules in LSIMS.  
These softer ionisation techniques still did not satisfy all possible conditions for 
biomolecular analysis, particularly for peptides and larger molecules, and thus laser desorption, 
and later matrix-assisted laser desorption ionisation (MALDI) were brought to the field, with 
the latter being still one of the most popular ionisation techniques used today. This technique 
is a powerful technique for the production of intact gas-phase ions from a broad range of 
biomolecules, including non-volatile, thermally unstable and large compounds such as 
proteins, oligonucleotides, and large inorganic compounds. As the name suggests, a matrix is 
required for MALDI, to provide for both desorption and ionisation, which are crucial for the 
success of the ionisation.  
Many other ionisation techniques have since been developed with a range of different 
potentials and properties. Comparable to MALDI, electrospray ionisation (ESI) is also very 
popular with wide sample applicability, with a particular advantage that it does not require a 
matrix to enable ionisation. In lipid analysis, especially of phospholipids, ESI source is actually 
preferred as these molecules have low molecular weight (600 to 1000 Da), ideal to be analysed 
by ESI.  
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Electrospray ionisation is a method to dissipate a liquid sample in a homogeneous form, 
and was first described by Malcolm Dole, et al. [109], with the charged residue model capable 
of generate large molecular ion beams. The principles of the charged residue model were 
further reinforced in 1988 by John Fenn's group, in a paper demonstrating that it was possible 
to transfer large molecules, such as proteins, as intact ions into the gas phase using an improved 
ESI source [110]. Another model for how the electrospray can generate ions from charged 
liquid droplets was originally developed by Iribarne and Thomson to explain the generation of 
atomic ions from randomly charged droplets produced by a spray atomizer (called ion 
evaporation model) [111].  
The basic principles of electrospray are the injection of the sample into a capillary tube, 
and a fine jet spray of ion droplets is obtained by applying a strong electric field (high voltage) 
under atmospheric pressure to the liquid sample, inducing charge accumulation at the liquid 
sample, forming charged droplets. The use of a nitrogen gas will make the dispersion of the 
spray limited in addition to assist solvent contained in the droplets to evaporate gradually and 
their charge per unit volume to increase. The droplet elongates due to the effect of the electric 
field gradient resulting from the accumulation of charge and forms what is called the Taylor 
cone (Figure 1.3.3) followed from a release of smaller droplets. From these small and highly 
charged droplets, the solvent continues to evaporate until each droplet corresponds to a single 
charged ion normally (depending on the properties of the molecule can be also multiple charged 
ions) [112].  
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Figure 1.3.3. An electrospray ion source with the mechanism of ionisation process (adapted from 
[113]). Description of the different components of an ESI source with detailed explanation of ion 
formation from multiple charged molecules to single charged analytes.  
 
Similar to the ESI source, Takats et al developed the desorption electrospray ionisation 
source (DESI) in 2004 [114]. This recent technique belongs to the group of ambient ionisation 
techniques in mass spectrometry in which samples are ionised in the ambient environment with 
minimal pre-treatment. In DESI, electrically charged droplets are used to ionise the molecules 
at the surface of a sample, which are then analysed with conventional mass spectrometers 
[114]. When the spray impacts the sample, a thin layer of solvent is formed into which the 
sample analytes are dissolved. With other primary droplets arriving at the sample surface, the 
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impact leads to the subsequent formation of secondary microdroplets containing the dissolved 
analytes from the solvent film facilitated by the nebulising gas (Figure 1.3.4).   
 
 
Figure 1.3.4. Desorption electrospray ionisation source scheme (adapted from [114]) 
 
 
Mass analysers  
 
After sample ionization, ions need to be separately detected according to their mass-to-
charge ratios (m/z), the main function of the mass analysers. There are a variety of mass 
analysers as there is for the ion sources with their advantages and limitations. Table 1.3.2 
describes the main characteristics of the different types of analysers currently available.  
Commonly-used mass analysers for the analysis of metabolites and lipids are 
quadrupoles, ion traps, time of flight (TOF) instruments, Fourier transform ion cyclotron 
resonance (FTICR) and Fourier transform Orbitrap instruments.  
Quadrupole analysers use the stability of ion trajectories in oscillating electromagnetic 
fields to separate ions according to their m/z ratios. The electrical field is applied between four 
parallel rods, to which current is applied and varied to direct the trajectory of ions to target the 
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desired mass range. Quadrupoles have the advantage of being relatively low-cost, easy to use 
and capable of providing accurate results. However, their resolution is limited, and their 
transmission decreases linearly, being the upper limit m/z of around 2000-3000 [115]. 
 
Table 1.3.2. Different mass analysers and their characteristics [105] 
Type of 
Analyser Symbol 
Principle of 
Separation 
Mass 
Range 
Limit 
Mass 
Resolution  Accuracy  Pressure  
Magnetic 
sector [116] B Momentum  
20 000 
Th 100 000 <10 ppm 10 
-6
 Torr 
Quadrupole 
[115]  Q 
m/z (trajectory 
stability) 2000 Th 2000 100 ppm 10 
-5
 Torr 
Ion trap [117] IT m/z (resonance 
frequency)  4000 Th 4000 100 ppm 10 
-3
 Torr 
Time-of-flight  
[118] TOF 
Velocity (flight 
time)  
>1000 
000 Th 5000 200 ppm 10 
-6
 Torr 
Time-of-flight 
reflectron [119] TOF -R 
Velocity (flight 
time)  
10 000 
Th 20 000 10 ppm 10 
-6
 Torr 
Fourier 
transform ion 
cyclotron 
resonance 
[120]. 
FTICR m/z (resonance 
frequency) 
30 000 
Th 500 000 <5 ppm 10 
-10
 Torr 
Fourier 
transform 
Orbitrap [121]. 
FT-OT m/z (resonance 
frequency) 
50 000 
Th 100 000 <5 ppm 10 
-10
 Torr 
 
Ion traps were first described by Paul and Steinwedel in 1960 and adapted for use in  
mass spectrometers by Stafford et al [117]. It consists in a multi-pole, producing a three-
dimensional field where the ions are trapped. In this analyser, the potentials are adjusted so that 
only the ions with a selected mass travels through the multi-pole rods. Consequently, ions with 
different masses are present together inside the trap until they are removed by collision. To 
make them leave, an ascending radio - frequency of small amplitude voltage is applied and the 
ions are expelled according to their masses resulting in the mass spectrum.  
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The analyser TOF was first described by Stephens in 1946 [118] and is characterised 
by using the different times that accelerated ions take to reach the detector based on their mass 
differences. The ions are accelerated by pulsed electric field and the accelerated particles pass 
through a flight tube. When leaving the accelerated region, they enter into a field free range 
where they are separated according to their velocities. As all ions acquired the same kinetic 
energy, so the m/z ratios are determined by measuring the time that the ions take to move 
through a field-free region between the source and the detector. As such the ions will travel at 
speeds inversely proportional to the square roots of their masses.  
FTICR and Fourier transform Orbitrap (FT-Orbitrap) are the analysers with highest 
mass resolution which determine the m/z, based on the Fourier transforms of the harmonic 
oscillations of the ions as they circulate inside the detector. The principle of these two analysers 
is based on the cyclotron frequency of the ions in a fixed magnetic field produced by a 
superconducting magnet. The ions are trapped in the magnetic field where the radius of the 
curved trajectory is proportional to the velocity of the ion. By measuring the cyclotron 
frequency of harmonic ion oscillations along the axis of the electric field, the mass of the ion 
can be determined. The difference in the FTICR and FT-Orbitrap is in the way the frequency 
is measured, if by complex waves (FTICR) or complex Fourier transforms (FT-Orbitrap) [120, 
121].  
 
Detectors  
 
After the analyser, the ions signals are detected and transformed into a useful signal. 
The detector of the mass spectrometer generates from the incident ions an electrical current 
proportional to their abundance. Not just the mass but also the velocity and the charge are the 
characteristics detectors are based on.  
The first ion detectors being used consisted of photographic plates located at the end of 
the mass analyser. All ions of a given m/z would impact at the same place on the photographic 
plate making a spot. The darkness of the spot was indicative of the intensity of that particular 
m/z. This first detector was a direct measurement detector, which means it measures the direct 
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charge current that is produced when an ion hits a surface and is neutralized. Another detector 
with the same principle is the Faraday cup, characteristic of its robustness and precision but 
with lack of sensitivity.  
The other category of detectors are electron multiplier detectors, which use an electron 
multiplier to increase the intensity of the signal generated. These detectors, as the electron 
multipliers and electro-optical, are based on the kinetic energy transfer of incident ions by 
collision with a surface that in turn generates secondary electrons, which are further amplified 
to give an electrical current [104, 105].  
From these detectors, the most widely used are electron multipliers, since they have a 
lifetime exceeding a limit of detectable masses. The detector is connected to a computer that 
integrates the information received and converts it into a mass spectrum, which shows the ion 
mass / charge ratio on the abscissa (values of m/z), and the relative abundance of these same 
ions after a normalization in relation to the ion abundance on the ordinate  
For the FTICR and FT-Orbitrap analysers, the detection is already incorporated in the 
analyser, where the ions are detected by the image current they produce in the pair of metal 
plates within the mass analyser region. 
 
 
1.3.4. Mass spectrometry for the analysis of phospholipids and sphingolipids  
 
In this thesis, the focus is on the characterisation of phospholipids and sphingolipids. 
The combination of sensitivity, specificity, selectivity and speed makes MS an ideal technique 
for the analysis of these types of lipids. Lipids can be analysed with two different approaches: 
non-targeted (lipid profiling) or targeted analysis (specific quantification and characterisation) 
[122].  
A lipid profile (non-targeted) analysis aims to provide a general overview of all lipids 
present in cells, tissues or body fluids. Despite not being considered quantitative, the presence, 
absence or relative difference in the concentration of lipids can be very useful for making 
comparisons between biological systems, and for understanding the lipidome inventory and the 
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lipid pathways under different conditions [96]. In order to correctly identify the lipids present 
in the spectral profile, this approach has to be followed by tandem mass spectrometry, where 
each m/z of interest (the precursor ion) will be individually fragmented, resulting in a fragment, 
or group of fragments (the product ions). The different fragment patterns achieved with tandem 
mass spectrometry will allow the structural elucidation of the molecule and, consequently, the 
identification and characterisation of the different lipid species.  
Targeted lipidomics analyses focus mainly on the characterisation and quantification of 
a particular lipid or small group of related lipids of interest [123]. From these analyses, single 
reaction monitoring (SRM) and multiple reaction monitoring (MRM) are the most common 
methods used to target the compounds of interest. With these functions, the precursor ion plus 
specific fragment or fragments of that precursor are monitored, and the area of the 
chromatographic peak is proportional to the quantity of a compound in the sample. Comparison 
of peak areas in samples with those obtained from concentration curves using preparations of 
standard materials allows the relative quantification of different molecules, from small 
metabolites to longer compounds [124]. Absolute quantification is also possible to be 
performed if a lipid standard labelled of the molecule of interest is spiked to the samples with 
a known concentration [125-127].  
The fragmentation pattern and consequently, the identification and characterization of 
the lipid of interest is the essential key for the development of a target method. With 
electrospray as the elected ionization technique for the analysis of phospholipids, the different 
lipid classes have different affinities in both polarities, positive ion mode and negative ion 
mode, a factor that can restrict the number of lipids which can be included in a single targeted 
method.  
PC, PS, CL, PE and SM classes, and their lysophospholipid forms (i.e. without one of 
the two fatty acid chains) can be ionised in positive ion mode by ESI-MS, commonly producing 
[M+H]+ ions, an adduct produced when a molecule binds to a positively charged hydrogen ion. 
In this mode, the formation of both these ionic species and their product fragments are greatly 
affected by the concentration of ions in solution. Ions that can bind to phospholipids include 
Na+, K+ and Li+ and these adducts are thus commonly observed. Negative mode ESI-MS 
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favours the PI, PS, PG, PA, PE, CL and ceramide classes (as well as their lysophospholipid 
forms), with the most common ions formed being [M-H]-. The fragmentation patterns of these 
species in negative mode, generally result in a very elucidative structural information on the 
phospholipids. In negative ion mode, the fragmentation of the polar head and the fatty acids 
are readily observed, facilitating the lipid identification process [128-130]. Table 1.3.3 
illustrates a number of these characterising fragments. 
 
 
Table 1.3.3. Characteristic fragmentation of the most abundant phospholipid classes 
Class Head group Polarity 
Function for 
Analysis 
PC 
Phosphatidylcholine 
Choline Positive precursor m/z 184 
SM 
Sphingomyelin 
Choline Positive precursor m/z 184 
PE 
Phosphatidylethanolamine 
Ethanolamine 
Positive 
Negative 
neutral loss 141 Da 
precursor m/z 196 
PS 
Phosphatidylserine 
Serine 
Positive 
Negative 
neutral loss 185 Da 
neutral loss 87 Da 
PA 
Phosphatidic acid 
Acid Negative precursor m/z 153 
PG 
Phosphatidylglycerol 
Glycerol 
Positive 
Negative 
neutral loss 172 Da 
precursor m/z 153 
PI 
Phosphatidylinositol 
Inositol Negative precursor m/z 241 
 
 
 
1.3.5.  Mass spectrometry imaging  
 
More recently, mass spectrometry imaging (MSI) has been gaining importance due to 
its capability to provide not just the metabolic profile of a sample, but also spatial information, 
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such as the distribution of molecules across the sample surface derived from mass spectra 
collected over the sample area. MSI enables the simultaneous collection of both spatial and 
chemical information, thus providing the identity and location of a diverse range of 
biomolecules, such as peptides, drugs, lipids, etc. MSI can therefore facilitate the observation 
of chemical differences between various regions of the same sample.  
Several MSI techniques have been developed to date, with the most commonly used 
methods being MALDI, desorption electrospray ionisation (DESI), and secondary SIMS [131, 
132].   
SIMS was the first ionisation technique applied to surface imaging, and still remains 
the technique most capable of achieving very high spatial resolution (100 nanometer range). 
The high resolution of SIMS allows the investigation of single cells, subcellular organelles, 
and communities of cells. However, SIMS sample preparation remains a time-consuming 
process, particularly as the sample has to withstand analysis under high vacuum. As mentioned 
above, SIMS involves the generation of ions from a sample by bombarding it with a primary 
focus beam (generated by an ion gun), which penetrates the sample. SIMS is a surface-sensitive 
and hard ionisation process, but these features are the critical factors by which SIMS can 
perform 3D imaging in a single analysis [133].  
MALDI continues to be the MSI technique mostly commonly used, as it can be used 
for analysing a wide range of molecules, from lipids to complex proteins with a decent spatial 
resolution (approximately 1µm). In MALDI-MSI, the sample preparation requires that the 
sample is coated with a matrix material to absorb the wavelength of the laser to be employed. 
With the irradiation by the laser, ions from the sample surface are desorbed, and images can be 
produced from multiple single mass spectra acquired across the tissue section. Although 
MALDI techniques were originally performed under vacuum, atmospheric pressure MALDI 
(AP-MALDI) has been introduced to permit ionisation at atmospheric pressure. However, the 
additional sample preparation required for MALDI is less desirable, and can introduce bias and 
artefacts into the data. Sample preparation steps can thus influence the spatial distribution and 
degradation of the analytes during the analytical run [134-136].  
 
56 
 
Amongst MSI techniques, DESI imaging is becoming increasingly used, as it can be 
performed under atmospheric pressure conditions and does not require the use of ionisation 
matrices. These advantages mean less sample preparation is required, making this technique 
simpler to use and less prone to errors [137, 138]. As explained above, pneumatically-assisted 
electrosprayed droplets of solvent are directed onto a sample surface, wetting it and allowing 
analytes to dissolve. Subsequent droplet collisions at the surface then produce analyte-
containing secondary droplets, which are deflected into the mass spectrometer. Each pixel of 
spatial data is acquired from this process applied in a grid across the sample surface, allowing 
the systematic spatial analysis of a range of m/z values in the sample surface. The sample 
preparation for this technique can be as simple as the cryosectioning of each frozen tissue to 
have frozen tissue section with 10-20µm thickness mounted onto glass slides. 
This electrospray technique has been successfully used in previous studies [132, 139-
141] to ionise and detect lipids. With the particular aptitude of DESI-MSI for the analysis of 
lipids and small molecules, it has recently been used for different applications such as drug 
distribution discovery [142], characterisation of tissue in a histological level as well as a tool 
to better understand the biochemistry of different diseases such as cancer [139, 143]. In 
particular, tissue characterisation using lipid profiles has the potential to open new insights in 
the histopathology field, the current gold standard technique for cancer diagnosis [132, 139-
141].  
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Figure 1.3.5. Schematic representation of the main three MSI techniques and their main features 
(based on [144] and [145] ) 
 
1.3.6. Bioinformatic strategies and analysis   
 
The field of bioinformatics has provided MSI technologies with methods to overcome 
some of the previous limitations in the identification of new molecular markers of cancer 
development and progression. The most notable accomplishment of bioinformatics is the 
automated and rapid ability to measure compound distributions (and in some cases provide 
relative quantitation) with direct correlation to topological anatomical and histological features 
in tissues, even at the cellular level [146, 147].  
For this analysis to be performed, different chemo-informatics strategies have been 
developed, based on three main steps: 1) preprocessing of raw imaging data, to deal with 
analytical variance in the data, thus enabling improved information recovery; 2) the 
development of an image co-registration algorithm, for correlating MSI data with histological 
features; and 3) multivariate statistical analysis with localised biochemical feature extraction 
and robust tissue object recognition.  
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For MSI data sets the workflow for preprocessing consists of a series of steps which 
prepare and make the MS data of differing samples and runs comparable, manageable and 
reproducible and simultaneously account for bioanalytical complexities common to DESI-MSI 
platforms. The initial preprocessing is normally the filtering of noise-related peaks. This step 
is sometimes incorporated into a peak picking process, i.e. an algorithm that selects peaks and 
identifies m/z values. The aim is to reduce the number of m/z values by eliminating those values 
corresponding to noise signals or to non-specific baseline signals.  The following step is data 
normalisation, which scales each spectrum according to some factor (usually dataset-specific), 
for a better inter-comparison of intensities between different spectra. The most common 
normalisation used is total ion count (TIC). In this normalisation process the sum of all 
intensities for each spectrum is calculated and each m/z intensity is then divided by the sum 
value [148]. The utility of this method is debatable, as it can be compromised by the intensity 
of single outlier molecular ion peak. Median fold change normalisation has also been 
demonstrated to be the least compromised by the biological relevant changes, when compared 
to other methods, including TIC, local polynomial regression (LOESS) and quantile 
normalisation. Different normalisation methods have been compared previously, [149] and 
evaluation of their performance across different datasets have all clearly demonstrated the 
necessity of this crucial preprocessing step, and more importantly, how data-dependent the 
selection of normalisation method is.  
The last preprocessing stage in the workflow is the spectra alignment and / or accurate 
peak matching [134]. To compare peaks in different data sets a common anchor is needed to 
align them together before the comparison. Alignment is fundamental to correct small drifts in 
peak mass accuracy as, dependently of the instrument resolution and accuracy,  the m/z values 
can be slightly shifted, and very often this shift is non-linear [150].  
There are different algorithms proposed, as the peak alignment algorithm based on a 
hierarchical clustering idea [151], and the use of mean spectrum to find common peaks, which 
avoids the peak alignment step [152]. However they all follow the same properties for a good 
peak finding algorithm described by Chen et al [153]: a good common peak finding algorithm 
should have the following properties: (i) it can define a specific common feature X, by setting 
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appropriate boundaries on the m/z domain; (ii) any peak detected on a single spectrum within 
the boundaries should be identified as X; and (iii) the boundaries should be wide enough to 
include all peaks on an individual spectrum that correspond to X, but not too wide to cover two 
or more other features.  
 
For the last step, these highly multidimensional MSI datasets need effective techniques 
capable of rapidly extracting tissue-specific molecular ion patterns, in order to characterise and 
discriminate between the different classes in the analysis. These techniques can use a single 
variable to describe and summarize patterns in the data (univariate statistical analysis), or use 
a group of variables to describe and characterize the data across multiple dimensions / 
components (multivariate statistical analysis) [154].   
Univariate statistical analysis can be descriptive or inferential. Descriptive statistics 
describes and summarize the data to find emerge patterns without any relationship calculations. 
Examples of these analysis are the mean and median for measuring the central tendency across 
the data set, and standard deviation and variance to measure the dispersion in the data set. 
Graphical representations of these values, as boxplots, are very useful to perceive common 
patterns that can emerge from the data. Inferential analysis allows to make decisions 
(inferences) about a population based on observations on a smaller and representative dataset 
of the population. These tests, as t-test and ANOVA, can measure the significance of the 
variation found in specific variables and, depending if it is inside the threshold defined, the 
variable is consider significantly different or not between the groups [155].  
Multivariate statistical analysis is more complex and can stablish relationships across 
multiple variables in a data set. Current methods multivariate statistical analysis can be divided 
mainly into two different groups: unsupervised and supervised methods. The unsupervised 
methods, such as principal component analysis (PCA), can be applied without any prior 
knowledge of the groups, aiming to reveal the general structure of the data set [156]. For 
imaging datasets, PCA is used to investigate tissue patterns based on the differences between 
sample class lipidomic profiles, without taking into account prior histological assignment 
[157]. With PCA it is possible to illustrate the full dataset using scores representing the 
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dimension-reduced multivariate data for each sample, having transformed several hundred or 
thousand variables into a reduced set of principal components. These components reflect linear 
combinations and weighting of all observations in the dataset, measuring and explaining the 
variation in the data set through the different scores calculated. 
Another unsupervised approach to look for imaging data is with spatial segmentation, 
where regions with different molecular pattern are colour coded, i.e., by grouping all spectra 
according to their similarity using a cluster algorithm [158]. One example of a cluster algorithm 
already used for imaging data sets is hierarchical clustering [159]. One advantage of this 
technique is that provides a grouping of the spectra into different classes representative for 
different tissue features. As such clustering results are presented in the form of a dendrogram 
which can be interactively analysed.  
The use of supervised methods requires classification data for group membership of 
each spectrum in order to find the m/z values which are differentiating the groups. The 
supervised method mostly used is partial least-squares (PLS) [160]. PLS is a regression 
extension of PCA which also maximises the variance between classes, by correlation and 
weighting of observation variables with group information. Discriminant analysis can be 
applied to PLS (PLS-DA) where sample groups are categorical. While PLS computes latent 
variables that contain mixed sources of variation, orthogonal-PLS (OPLS), an improvement of 
PLS, decomposes the structural variation into predictive and orthogonal. As such, OPLS brings 
more understanding regarding the variance in an experiment [161].  
Another supervised method widely used is linear discriminant analysis (LDA), where 
it is capable not just of maximising the differences between class means but also 
simultaneously minimising the variability within-class [162]. Unfortunately, LDA cannot be 
directly applied in circumstances where the number of variables exceeds the number of 
samples, a very common situation in MSI datasets. Recently the method recursive maximum 
margin criteria (RMMC) was described as ideal for these MSI datasets [163], as it is capable 
of maximising the variance between classes, and also to explain the variability within class, 
crucial in analysis with a spatial dimension. The advantage of RMMC with respect to other 
widely used discriminant analyses was recently demonstrated (Table 1.3.4, [163]). 
 
61 
 
 
Table 1.3.4: The relationships of widely applied supervised and unsupervised dimensionality 
reduction techniques in metabolic phenotyping studies via eigenvalue decomposition 
Method Eigen-value 
decomposition 
Components derivation 
PCA  [St]w = w  Maximizes overall dataset variation (St), without 
specific regard to between-class differences  
PLS  [Sb]w = w  Maximizes between-class variation (difference in 
class means Sb), disregarding within-class 
variability 
LDA  [Sw
-1Sb]w = w  Maximizes ratio of between- versus within- class 
variation (Sw), with the condition that within-class 
variance is non-singular (i.e. number of samples 
>> number of variables) 
RMMC  [Sb - Sw ]w = w  Maximizes the difference of between-class within-
class variation 
 
 
Overall there is an increase of mass spectrometry imaging studies in different areas, 
such as instrumental development, data analysis and clinical application for cancer diagnosis 
and biomarker discovery. However, cancer biochemistry and the lipidome of this disease is 
still yet to be fully understood.  
 
  
Chapter 2  
Hypothesis / Aims  
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2. Hypothesis / Aims  
 
Based on the state of the art exposed during the first chapter it is hypothesised that 
spatially resolved molecular phenotypes (i.e. distribution of lipid species in the tissue) can be 
measured by modern mass spectrometry technologies such as DESI-MSI. These molecular 
phenotypes can capture the systems biochemistry in different types of ovarian cancer and can 
be used as diagnostic tool to complement current histology-based techniques.  
 
This hypothesis can be divided into three specific statements:  
• Different cancer types at diverse cancer stages exhibit different lipid profiles 
with different molecular patterns and distributions.  
• The characteristic lipid profiles of each cancer type can be detected by LC-MS 
and DESI-MSI analysis, and with the latter technique, also the distribution of 
lipids in cancer tissues.  
• DESI-MSI can be used as a tool for histology-level ovarian cancer diagnostics 
and prognosis.  
 
To investigate and support the hypothesis, it is aimed for this study to investigate the 
lipid biology and distribution in ovarian cancer in a top-down systems approach to improve 
diagnosis and prognosis of this disease. To achieve this aim, the specific objectives are: 
1. Characterise the lipid profile of different tissue types in EOC by DESI-MSI. With 
the specific lipid fingerprint of the different tissue types in EOC we would be able 
to identify the different types of ovarian malignancies, as well as the aggressiveness 
of the tumour, giving histopathology another diagnostic tool based on the molecular 
map of the tissue.  
2. Develop different MS targeted methods to complement the lipidomic approach, and 
to simplify interpretation of the MS profiling spectrum achieved in the current 
DESI-MSI method. This aim is divided into two different approaches: a) develop 
an LC-MS targeted method for phospholipids and sphingolipids to support the lipid 
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changes found in DESI-MSI; b) to attach a triple quadrupole instrument with a 
DESI stage to achieve tissue characterization based on a simpler, faster and cheaper 
instrument, targeting just a selected number of molecules which are of specific 
interest.  
3. Investigate the lipid metabolism in cancer with the different lipid changes found in 
ovarian cancer samples using DESI-MSI, complemented by targeted LC-MRM and 
with other techniques such as immunohistochemistry. The lipid changes should be 
linked to different biological functions and roles in the different pathways with the 
semi quantitative LC-MRM data acquired. Some of the enzymes responsible for the 
phospholipid pathways as well as for fatty acid synthesis will then be analysed by 
immunohistochemistry assays.  
 
 
   
Chapter 3  
Ovarian cancer diagnosis by DESI-MS 
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3. Ovarian cancer diagnosis by DESI-MS  
 
3.1. Introduction  
 
Histopathology continues to be the gold standard technique for the cancer diagnosis. In 
case of the ovarian cancer, the detection is primarily based on medical imaging and serological 
biomarkers, such as a blood test for the carbohydrate antigen-125 (CA125). Once the presence 
of a tumour has been confirmed, its diagnosis (malignant potential) must be determined through 
exploratory laparotomy and subsequent biopsies. Histological information is then provided by 
a pathologist and complemented by further diagnostic tests [15]. One major issue in diagnosis 
is that this technique is based on histopathologist interpretation and can vary from one 
histopathologist to another, it can lead to some uncertainty and sometimes to a vague prognosis. 
DESI-MSI has shown to be a powerful technique to characterise and reveal the 
biochemistry of different tissue types. This technique has the capability of not just 
characterising the lipidomic profile but also localize these lipids in a spatial resolved manner. 
As this information is based on the biomolecular composition, it is user independent and so 
less prone to error. Furthermore, it discloses tumour biochemistry in a different perspective, 
allowing to comprehend further into the cancer metabolism and possibly identify specific 
biomarkers for certain tissue types. DESI-MSI has the potential to identify tumour subtypes 
and stages, revealing the lipidomic profile of each tissue type [139].  
There are already several examples of tissue characterisation and successfully 
identification of their unique metabolic profile by DESI-MSI. The first example, as mentioned 
above, was performed in metastatic human liver adenocarcinoma samples [164]. Since then, 
there was a diverse range of cancer types characterised by this technique, as brain tumours, 
colorectal cancer [137], breast cancer [139], lung cancer, etc. [140].  
In the case of ovarian cancer, this was the first study preformed with DESI-MSI and 
published [165]. As such, the aim of this chapter is to evaluate the potential of DESI-MSI to 
characterise and identify the different tissue types found in EOC samples, to complement 
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pathology and possibly the beginning of a new tool for a more precise EOC diagnosis and 
prognosis.  
 
 
3.2. Methodology  
 
3.2.1. Clinical patient data 
 
The collection of all samples for this study was approved by the institutional review 
board at Imperial College Healthcare National Health Service Trust (Tissue Bank sub-
collection number GYN/HG/12/060). All patients provided informed consent to the use of their 
samples in this study, and all methods were performed according to institutional and ethical 
guidelines. Patients undergoing gynaecological surgery were recruited and 89 tissue samples 
were taken from a range of borderline and EOC tumours. Normal control samples included 
tissue from normal ovaries (n=15) and fallopian tubes (n=6). All tissue samples were stored at 
-80°C after collection (Table 3.2.1) and first histopathological assessment. 
 
Table 3.2.1. Number of patients and samples used during this study. 
  Number of samples Number of patients 
Normal  Ovary  15 13 
Fallopian tube 6 6 
Borderline 11 11 
Malignant  
Serous 65 65 
Endometrioid 7 7 
Clear cell 6 5 
 
3.2.2. Sample preparation and mass spectrometry analysis 
 
Each sample was cryosectioned (using a Bright 5030 cryotome (Bright Instruments, 
Cambridgeshire, UK)) to a thickness of 12 μm, mounted onto a glass slide (Superfrost glass 
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slides, Thermo Fisher) and stored at -80oC prior to DESI-MSI measurement. After DESI-MSI 
measurement, tissue sections were stained with hematoxylin and eosin (H&E) and underwent 
histological examination by a histopathologist.  
For DESI-MSI analysis, tissue sections were thawed under nitrogen flow. DESI-MSI 
was carried out using a home-built DESI ion source coupled to an Exactive Fourier transform 
Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany). The DESI-MSI was 
operated at a spatial resolution of 100 μm (injection time of 1000 ms) using nitrogen pressure 
of 7.0 bar, sprayer voltage of 4.5 kV, capillary voltage 50 V, capillary temperature of 250°C, 
tube lens voltage of 150 V, and skimmer voltage of 40 V and a solvent mixture of methanol 
and water in a ratio 95:5 (v/v) with a flow rate of 1.5 μL/min. The mass analysis was carried 
out in negative and positive ion mode in the mass range m/z 150–2000 at a nominal mass 
resolution of 100,000 and a mass accuracy of ± 2ppm. Each sample had between 40 and 150 
mm2 acquired with a speed rate of 100 μm/s. The sample run order was randomly determined 
such that similar samples were not run consecutively.  
 
3.2.3. Sample processing  
 
Following DESI-MSI acquisition, raw mass spectrometric images were converted to 
imzML format [166] using imzML Converter (version 1.0.5) and imported into MATLAB 
(R2014a), MathWorks, for pre-processing and analysis [163]. 
The tissue types present in each sample were determined following examination of the 
H&E-stained image by an independent histopathologist. Each histological image was co-
registered to the DESI-MS image in order to facilitate histological annotation. A region of 
interest within both the H&E optical image and matched ion-image was selected by the 
histopathologist and all pixels/spectra within the region were assigned histological type and 
used in subsequent multivariate analyses.  
The spectral profiles within the m/z region of 600–1000 were aligned using an in-house 
developed peak-matching procedure subject to a maximum peak shift of 8 ppm.  Mass spectra 
from the same tissue and the same section were averaged (mean) and TIC normalised. 
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These averaged spectral profiles were analysed by PCA and RMMC linear 
discriminants analysis [163]. RMMC was used for supervised discrimination and robust 
classification of spectra was performed using a leave-one-patient-out cross-validation scheme. 
In such a scheme, a supervised model is generated with data from all but the left-out patient. 
This model is then used to predict the spectra from the omitted patient, and the classifications 
are compared to the histopathologist annotations. These results are presented as confusion 
matrices showing the actual and predicted classifications of each spectral profile. 
Discriminating spectral variables were determined by inspection of the component weights in 
conjunction with false discovery rate-corrected univariate statistics (analysis of variance, 
ANOVA) in order to control and correct the false positive results. 
The variables found to discriminate significantly between tissue types were 
subsequently subjected to spectral annotation. This was performed using exact m/z values and 
isotopic distributions via database searches (Metlin [167], Lipid Maps [168], HMDB [169]). 
 
 
3.3. Results and Discussion  
 
3.3.1. DESI-MS and spatial tissue identification based on the lipidome  
 
Diagnosis is a crucial step in ovarian cancer; as the patient journey is decided based on 
tissue analysis. Histopathology is the gold standard procedure for tissue biopsies and has shown 
that EOC comprise 90% of the ovarian cancers.   
To better compare and link the lipidomic profile with the morphological features, 
optical images were aligned with ion images and examined by a qualified histopathologist for 
precise selection of morphological regions of interest. Figure 3.3.1 shows the different average 
spectra from all regions of interest belonging to the tumour tissue and healthy ovarian 
connective tissue (stroma) for both MS polarities analysed. Observing these spectra, it is 
possible to observe certain ion changes in their relative abundances from one class to another. 
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For the different polarities, both positive and negative ion mode acquisitions, analysed by 
DESI-MSI, adjacent sections were used. The most abundant classes of phospholipids in 
negative ion mode for the samples were PS and PE, followed by PG and PI. In positive ion 
mode the spectra were dominated by PC with an average intensity always more than two times 
higher compared to the second most abundant class, PE (based on accurate m/z matching with 
lipid databases such as Metlin, Lipid Maps and HMDB).  
 
 
Figure 3.3.1. Average relative intensity of DESI-MS spectra from multiple samples in both negative 
and positive ion mode. Samples analysed were divided in two different groups: serous ovarian 
carcinoma samples (red) and healthy ovarian stroma samples (green).  
 
Positive ion mode can provide complementary information related to some 
phospholipid classes which do not ionise so easily in negative ion mode. However, the intensity 
of the PC class, one class we see with very low intensity in negative ion mode, dominates the 
lipid profile in positive ion mode. As such, it is difficult to achieve good intensity for other 
lipid classes, creating a less diverse lipid profile compared to the negative ion mode. For this 
reason the negative ion mode is normally the selected spectrum for characterisation and 
identification of different tissue types analysed by DESI-MSI [139, 140, 163].  
The spatially resolved nature of DESI-MSI permits identification and prediction of 
different tissue types within what may be considered to be macroscopically homogenous tissue. 
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In our study different regions of interest were delimited and different tissue types were found 
across the samples (epithelial carcinoma tissues and borderline tumour tissues, the respectively 
surrounding stroma, the epithelial tissue from fallopian tube and healthy (“control”) stroma 
from normal ovary). Figure 3.3.2 shows the average spectra of the four most abundant tissue 
types in negative ion mode.  
 
 
 
The distribution of the different ions found in the different spectra can be accessed, 
revealing their unique localization in the different tissue types. Figure 3.3.3 shows the ion maps 
of different lipid species, in both normal ovary and high grade serous ovarian carcinoma 
samples. In this figure, m/z values belonging to five different lipid classes with different 
distributions across these different tissue types were chosen.  
Using the histologically annotated regions of interest, it is possible to observe the lipids 
which are present between normal and tumour samples and also the tumour regions compared 
to the surrounding areas.   
Figure 3.3.2. Average spectrum in negative ion mode for the four most abundant tissue types, a) serous 
ovarian carcinoma tissue, b) serous ovarian carcinoma associated stroma, c) healthy epithelial cells from 
fallopian tube and d) healthy stroma from ovary. 
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It is possible to observe that not all lipid classes have the same behaviour, neither inside 
each class. For example, in the PS class the m/z value of 760.51 is more expressed in the normal 
ovarian sample, whereas the PS with m/z value of 836.55 is more expressed in the serous 
carcinoma sample. Furthermore PEs with m/z value of 762.51 and 796.59 present a very low 
expression in the normal samples compared to the serous carcinoma samples, precisely the 
opposite of the m/z value of 748.53. In the PI and more obvious on the PA class, all m/z values 
demonstrated in the figure 2.3.3 have a higher expression in the serous carcinoma sample 
compared to the normal sample. In the ceramide class the m/z value of 682.59 is substantially 
more expressed in the normal ovarian sample, the contrary of PI and more obvious on PA class, 
where all m/z values demonstrated in the figure 2.3.3 have a higher expression in the serous 
carcinoma sample compared to the normal sample. Curiously in the PI class, it is possible to 
observe a higher expression of the m/z values in in the tumour regions compared to the 
surrounding tissue (stroma), not so obvious on the PA class, whereas the distribution of the 
ions is more homogenous across all tumour sample.  
The different changes found in this simple ion distribution analysis across all samples, 
were very similar, demonstrating the powerful ability of these lipids to characterise each 
individual tissue.  
The different histologically annotated regions of interest were also used for statistical 
analysis, to evaluate how different the diverse tissue types found in a sample section are. In the 
control samples, most of the sections were constituted by two tissue types, connective tissue 
(stroma) and corpus albicans, as we can observe in the Erro! A origem da referência não foi 
encontrada.. This analysis was performed in both negative and positive ion modes.  
 
Figure 3.3.3. Ion images of different m/z values with the respective putative identification based on online data 
bases. Comparison of relative intensities between normal ovarian sample and serous carcinoma sample. 
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Figure 3.3.4. Normal ovary tissue sample with two diﬀerent tissue types, normal stroma (annotated in 
green) and corpus albicans (annotated in yellow). Data acquired in negative ion mode and positive ion 
mode. (a) and (e) Optical images and (b) and (f) PC analysis of selected regions of interest. (c) and (g) 
predicted RMMC components with (d) and (h) leave-one-out cross validation 
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The different samples were also analysed by multivariate statistical analysis. The first 
sample described is a normal ovarian sample, where it was possible to observe two distinct 
tissue types: stroma and corpus albicans. When comparing these tissue types with an 
unsupervised analysis (PCA) there is a distinct separation between the stroma and the corpus 
albicans, having the first component explaining more than 60% in both positive and negative 
ion modes. Using the histologically annotated pixels in each tissue section, a sample’s 
remaining pixels / spectra can be classified using supervised multivariate analyses performed 
on each individual sample’s data-set. Each spectrum is evaluated against the RMMC model 
and classified according to the similarities / differences of the given model. Comparing the 
observed histology in the H&E image with the pixel predictions, the results are clearly in line, 
demonstrate that there is a clear difference between the two lipid profiles (Figure 3.3.4c and 
g). The pixels annotated were also subjected to supervised analysis RMMC, and the high cross 
validation for these samples validate again how the lipidome of this tissue types is different.  
The same approach was performed for all tumour samples, allowing to distinguish not 
just the tumour regions but also the surrounding stroma. For serous tumours, two types of 
tumours were collected, as borderline ovarian tumours and high grade serous carcinoma of 
ovary. In these samples we observed that the first component of the PCA in the negative ion 
explains a higher percentage of the variation of the spectral content compared to positive ion 
mode. When comparing the stained H&E image with the RMMC predicted image we can 
match perfectly regarding the two tissue types found in this samples, the stroma and the tumour 
areas. Interestingly, when supervised analysis was performed, the cross validated scores are 
very similar in positive and negative ion mode, being slightly better in the last one. For this 
reason, we can demonstrate the importance of the lipid profile found with this analysis for the 
tissue differentiation and characterisation.  
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Figure 3.3.5. (I) Serous borderline tumour and (II) serous carcinoma with two tissue types in each 
sample. Data acquired in negative ion mode (a, b, c and d) and positive ion mode (e, f, g and h). (a) 
and (e) Optical images and (b) and (f) PC analysis of selected regions of interest. (c) and (g) predicted 
RMM Components with (d) and (h) leave-one-out cross validation 
 
 
After serous tumour type, clear cell carcinomas and endometrioid carcinomas are the 
other two types of EOC. They comprise 15% - 20% of the EOC in western countries [17]. The 
same analysis was applied to these carcinomas types, where the tumour and the stroma continue 
to separate with an overall accuracy of 100%.  
 
(I) 
(II) 
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Figure 3.3.6. (I) Clear cell carcinoma and (II) Endometrioid carcinoma with two tissue types in each 
sample. Data acquired in negative ion mode (a, b, c and d) and positive ion mode (e, f, g and h). (a) 
and (e) Optical images and (b) and (f) PC analysis of selected regions of interest. (c) and (g) predicted 
RMM Components with (d) and (h) leave-one-out cross validation 
 
Interestingly the negative ion mode continues to explain slightly more the separation 
between carcinoma and associated stroma tissues compared to positive ion mode. This 
observation can be demonstrated by the PCA, where the component one is higher in both 
carcinomas in negative ion mode compared to positive ion mode. The diversity of the negative 
ion mode spectrum is once more an advantage for the characterisation of these different tissue 
types. For this reason, the multiple sample comparison models will be shown in negative ion 
mode, being the spectrum composition analysed more in depth in the chapter five, the lipidomic 
analysis of ovarian cancer.  
(I) 
(II) 
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PCA was then applied to identify overall similarities/differences in lipid composition 
between different tissue regions in all sample surface without any prior information in the 
analysis. The resulting principal component scores for every pixel in the tissue section were 
visualized in a color-coded manner with the colour intensity proportional to the score of a given 
pixel. The lipid profile demonstrated different chemical regions correlated with the histological 
regions marked previously as we can see in Figure 3.3.7 in a high grade serous carcinoma 
sample. For most of the samples, the first principal component could already differentiate the 
tumour tissue on the sample surface.  
 
 
Figure 3.3.7. Differences in the chemical distribution across the sample surface of a high grade serous 
ovarian carcinoma sample according to the first two components in a PCA analysis. Comparison with the 
two first RMMC components, the tumour tissue component and the connective tissue / stroma component in 
two different colour schemes.  
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3.3.2. Multiple sample comparison   
 
The first question needed to be answered on this cohort is how different the tumour 
tissue is from the healthy tissue; how far can the lipidome characterise these tissue types across 
the heterogeneity of different patients.   
 
Figure 3.3.8. Statistical analysis of DESI MS spectra between 600-1000Da from all carcinomas 
together (Cancer), healthy stroma from healthy ovary (Healthy OV) and healthy epithelium from 
healthy fallopian tube (Healthy FT). A) Principal component analysis (PCA) and B) Maximum 
margin criteria analysis (RMMC) cross validated with the respective C) leave one patient out cross 
validation using Mahalanobis as classifier 
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For this purpose, a statistical model was built with the tumour regions marked in all 
cancer samples as well as the stroma from normal ovary and epithelial tissue from normal 
fallopian tube. These analyses, unsupervised PCA followed by maximum margin criteria 
supervised (RMMC), were based on the three most abundant EOC: serous, endometrioid and 
clear cell carcinomas. Specific regions classified as carcinoma by histopathology were selected, 
as was stroma from normal ovaries histologically classified as “normal”. Normal ovaries have 
only a very small portion of epithelial cells, a thin layer surrounding the connective tissue 
(stroma). The above types of ovarian cancer have their origin in epithelial cells, therefore 
epithelial cells from normal fallopian tube were also analysed together with normal ovary as 
another control group.  
The cellular origin of EOC has been long debated as these tumours are derived from 
müllerian ducts and are therefore müllerian derived epithelial tissue rather than mesodermal 
epithelium from which the ovaries develop [20]. The recent literature for that reason suggests 
that EOC is not derived from the ovarian surface epithelium (mesodermal), as originally 
thought, but derives from müllerian-type tissue (cervix, endometrium, and fallopian tubes) 
[19]. Unfortunately, in this study, it was impossible to collect ovarian surface epithelium to 
evaluate which epithelial tissue would be most similar to the tumour in order to support the 
fallopian tube origin theory described above.  
The results of the PCA shows already a clear separation between the carcinoma samples 
and both healthy samples. With the cross validated RMMC it was possible to achieve a 
separation of all 3 classes with overall accuracy of 98%.  
Borderline ovarian tumours tissue, are often difficult to discriminate from carcinoma as 
they share many similar characteristics. As such, it would be beneficial to develop robust tools 
to accurately identify borderline tumours by characterising their shifting metabolism towards 
carcinoma. For this reason, a multivariate analysis of normal, borderline and carcinoma 
samples was performed (Figure 3.3.9), and their similarities / differences were accessed.  
In the PCA model we can observe that carcinoma samples are once more completely 
separated from the normal stroma from normal ovaries. However, borderline tumours are one 
part mixed with the healthy stroma, and other more closed to the carcinoma samples.  
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The supervised RMMC analysis in Figure 3.3.9 shows a much clearer continuum from 
normal to carcinoma, through borderline, tissue types. The confusion matrix of the cross 
validated RMMC shows an overall accuracy of 91%, with none of the misclassifications being 
between the carcinoma and normal pixels.  
 
 
Figure 3.3.9. Statistical analysis of DESI-MSI spectra between 600-1000Da from all carcinomas 
together (Cancer), borderline tumours (Borderline) and healthy stroma from healthy ovary (Healthy 
OV). a) Principal component analysis (PCA) and b) Maximum margin criteria analysis (RMMC) 
cross validated with the respective c) leave-one-patient-out cross validation results. 
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Borderline tumours can be difficult to diagnose, which may explain the borderline 
tumour samples being misclassified as carcinoma and vice versa in the model [170]. The 
supervised classification results point to there being differences in the lipidomic profiles across 
the continuum of these three tissue groups. This represents altered metabolism in these tissues 
and may give insight into the underlying biological mechanisms responsible for the 
pathogenesis of malignancy in ovarian tissue. 
 
Figure 3.3.10. Statistical analysis of DESI-MS spectra between 600-1000Da from three different 
types of carcinomas (clear cell carcinoma – Clear Cell, endometrioid carcinoma – Endometrioid, and 
serous carcinoma – Serous) together with healthy stroma from healthy ovary (Healthy OV). a) 
Principal component analysis (PCA) and b) Maximum margin criteria analysis (RMMC) cross 
validated with the respective c) leave-one-patient-out cross validation results. 
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The other two epithelial carcinoma types collected were also compared to evaluate their 
differences based on their lipidome. As explained above, serous carcinomas are the most 
common type of EOC, resulting in a lower proportion of patients / samples from endometrioid, 
clear cell and mucinous carcinomas.  
Despite the low number of samples from the endometrioid carcinoma and clear cell 
carcinoma groups, it was possible to analyse the three EOC types along with normal ovarian 
tissue (Figure 3.3.10).  
From a lipidomic perspective, serous carcinoma is highly distinct from both clear cell 
and endometrioid carcinomas, already observed in the PCA model. However, these latter two 
are essentially indistinguishable from each other when comparing as it is possible to observe 
on the cross-validation scores. This could stem from the fact that these two cancers usually 
coexist in the tumour and also from the low sample numbers in this study. 
Additionally, recent studies have suggested that both clear cell and endometrioid-type 
carcinomas of the ovary are likely to arise from endometriosis [21] one possible explanation 
why metabolic changes in these tissue types seem to be identical. Although some studies have 
tried to explain the different histogenesis of endometriosis for endometrioid and clear cell 
carcinomas [23], this dichotomy is far from being completely understood. 
Unfortunately, in-depth analysis of endometrioid and clear cell cancer was limited in 
this study by the small sample size, reflected by the small number of patient samples available 
in the study.  
 
 
3.3.3. DESI-MSI as a diagnostic tool 
 
The power of this technique on the classification of different sample types was already 
demonstrated above, emphasising how DESI could be used to complement histology, on an 
automated and human independent manner.  
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Figure 3.3.11. Statistical analysis of DESI-MSI spectra between 600-1000Da from serous carcinoma 
together with serous carcinoma associated stroma and normal stroma from healthy ovary. Principal 
component analysis (PCA) and Maximum margin criteria analysis (RMMC) cross validated with the 
respective leave one patient out cross validation results. 
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The next step is to evaluate the efficiency of DESI-MSI to correctly classify different 
tissue types comparing multiple samples together. For this purpose, the class of samples with 
higher incidence, serous high-grade carcinoma type, were used to perform statistical analysis 
and calculate how different / similar these tissue types are. In a first stage of the study the 
analysis of 70 samples containing 3 different tissue types was performed: serous carcinoma, 
carcinoma associated stroma and normal ovary. Histopathologist-annotated spectra across the 
various samples were peak matched, normalised and log transformed prior to multivariate 
analysis as for the previous analysis. Multivariate analysis was first performed on a subset of 
samples. This analysis was performed in both negative and positive ion mode as we can observe 
in Figure 3.3.11.  
The PCA scores plots for positive ion mode showed no clear separation between the 
three different classes. This can be explained due to the sample variability and also to the 
chemical heterogeneity in the spatial distribution of molecules in each sample. Interestingly, in 
negative ion mode, the first two components already differentiate the three different areas 
classified. A supervised analysis (RMMC) was performed to extract tissue-specific molecular 
ion patterns capable of discriminating between histologically defined pixels. Leave one patient 
out cross validation was performed to evaluate the separation. All the tissues can be separated 
with an overall accuracy of around 83%. Although in negative ion mode, the different tissue 
types could already be separated in the first two principal components, the overall cross 
validation shows similar score in both negative and positive ion mode. The number of control 
samples is limited, thus increasing the number of samples on the model might improve the 
model and achieve better scores.  
In a later stage of the study, the sample size was extended to 110 with the collection of 
more controls, not just normal ovaries but also epithelial tissue from fallopian tube. As 
explained above, serous ovarian carcinoma is an epithelial type of ovarian cancer, gaining 
another control class with the analysis of epithelial tissue from the fallopian tubes. Figure 
3.3.12 shows the results of the statistical analysis performed using now four distinct tissue 
types: serous carcinoma, carcinoma associated stroma, normal fallopian tube and normal ovary. 
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Once more, histopathologist-annotated negative ion mode spectra across the various samples 
were peak matched, normalised and log transformed prior to multivariate analysis.  
 
 
 
Figure 3.3.12. Statistical analysis of DESI-MSI spectra between 600–1000 Da from serous carcinoma 
samples with two tissue types (stroma and carcinoma) together with normal stroma from normal 
ovary and normal epithelium from fallopian tube. (a) Principal component analysis (PCA) and (b) 
Maximum margin criteria analysis (RMMC) (c) RMMC analysis after excluding the three normal 
appearance stroma from cancer patients with respective (d) leave one patient out cross validation 
results.  
 
Whilst there is a noticeable degree of overlap in the PCA scores plots (Figure 3.3.12) 
of the four tissue types, the second component does show a trend separating the two normal 
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tissue types (fallopian tube and ovary) from the carcinoma associated stroma and serous 
carcinoma. However, the cross validated RMMC shows a clear separation between the 4 
different tissue types, with a slight overlap between serous carcinoma and carcinoma associated 
stroma.  
Three samples, circled in Figure 3.3.12, were classified as normal ovary by the 
histopathologist but classified by RMMC as carcinoma-associated stroma. Interestingly, these 
three samples are from patients with ovarian cancer but distant from the histopathological 
sampling area and with similar appearance to a normal stroma according to the 
histopathologist. The lipidome of these stroma tissues with a normal appearance is closer to 
the tumour associated stroma than normal stroma. The metabolism of these patients is closer 
to the patients with carcinomas, emphasising the importance of not just to look to histology, as 
metabolism can be already changing, offering an opportunity to an earlier diagnosis. These 
misclassified samples were removed from all subsequent analyses (reducing the normal ovary 
class from 15 to 12 samples) as these samples were neither normal ovarian tissue nor actual 
tumour tissue.  
Upon removing these samples from the analysis, RMMC analysis (Figure 3.3.12 c) was 
used to classify the remaining samples and assessed by means of a leave-one-patient-out cross 
validation scheme. Figure 3.3.12 d) shows the confusion matrix for tissue type classification 
with an overall accuracy of 85.5%, with 100% classification the normal samples. The two 
tumour related tissues are clearly discriminated from the two normal tissue types by the first 
latent variable seen in Figure 3.3.12c. Curiously the second latent variable shows a noticeable 
separation between the epithelial related tissue types (fallopian tube epithelial tissue and 
carcinoma tissue) and the stoma tissue types (the normal ovary and carcinoma associated 
stroma from the cancer patients). This proximity of carcinoma tissue with the epithelial tissue 
from fallopian tube on the second latent variable is another indicator of the epithelial origin of 
these tumours. The comparison with different epithelial cell types was not possible as 
mentioned above, but the similarity of the carcinoma tissue with an epithelial cell metabolism 
is evident in the supervised analysis.  
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3.3.4. Pixel-wise classification of a blind sample 
 
The various leave one patient out cross validation analysis along the study have 
demonstrated to be able of predicting pixels within a sample and across multiple samples. For 
the use of this technique in a diagnosis perspective, the prediction of a totally unseen sample 
would offer a comprehensive histological diagnosis more quickly and objectively than could 
be provided by a histopathologist. Based on a previous model acquired, DESI-MSI could 
function as an identification tool for cancer diagnosis.  
The analysis of a completely independent sample was achieved using a training set 
derived from all previously analysed tissue samples, including the serous ovarian carcinoma, 
carcinoma-associated stroma and normal ovarian tissue types. The blind sample was analysed 
with a pixel size of 100 μm x 100 μm. An iterative one-class-against-all RMMC model was 
used to determine the probability of each test-set pixel belonging to each of the classes in the 
training set. Pixels with a single probability p > 0.99 were considered to be unambiguously 
classified. Those with p < 0.99 were unclassified as were those with multiple classifications 
with p > 0.99.  
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Figure 3.3.13. Prediction of an independent sample using as training set the previous model (serous 
ovarian carcinoma). (a) Optical image of the independent sample, (b) predicted image and (c) 
confusion matrix for classification of histopathologist-annotated tissue regions of interest  
 
 
The different classification matches are demonstrated in the 3.3.13 b), where the 
different colours represent the different tissue types. After this classification, the regions of 
interest of this blind sample were annotated by a qualified histopathologist, and the 
classification of these regions of interest (pixels) is shown in the confusion matrix in Figure 
3.3.12 c), where an overall accuracy of 99.6% was achieved. This example demonstrates the 
potential of this technique to predict unseen samples and complement histopathology. The 
acquisition and inclusion of further samples on the RMMC model will increase the robustness 
of the model and thus its predictive capacity. With a higher number of samples, then 
heterogeneity of the population is better represented which results in an improved classification 
performance, as we could observe from our first approach with fewer samples, and the increase 
of accuracy for the second model with higher number of samples.  
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3.3.5. The lipids behind the classification  
 
The lipids are the core of the characterisation of these different tissue types as we could 
observe in Figures 3.3.1 and 3.3.2. The DESI-MS spectrum is essentially composed by 
different class of lipids, majority phospholipids and sphingolipids. In the beginning of the 
chapter the average spectrum of the 4 different tissue classes could already indicate how 
different these lipidomes are from each other, such as, for example, the peaks at m/z 788.55 
and 682.59 showing higher abundances in normal tissues compared to the normal stroma and 
serous carcinoma tissue types.  
The multivariate statistical analysis described above allowed calculation of 
interpretable loading plots, showing the RMMC component weights for the latent variables 1 
and 2. These data are shown in Figure 3.3.14. The m/z values with the highest and lowest 
loading values from both latent 1 and 2 reveal the five distinct lipid classes which are 
responsible for the separation between the normal tissues and stroma/serous carcinoma tissues: 
PA, PS, PE, PG and Cer. 
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Figure 3.3.14. RMMC component weights for latent variables a) 1 and b) 2 m/z values with the 
highest loading values and mean log2 fold change equal or greater than 1 
 
Interestingly ceramides are the molecules with lowest loading values, which is 
translated to a high contribution to the separation of normal from carcinoma tissues. On the 
other hand, phosphatidic acid class is presented elevated in carcinoma compared to normal 
tissues. The impact of the PE class in differentiating these classes is also linked to their fatty 
acid chain length. For example, PE (38:6) and PE (40:3) corresponding to the m/z values of 
762.51 and 796.59 respectively, have positive values in LV1, increasing in carcinoma and 
carcinoma-associated stroma compared to normal tissue. In contrast, a lower chain PE, PE 
(34:0), have large negative weights in LV2 meaning they are decreased in cancer associated 
stroma compared to cancer tissue.  
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To better understand the modifications on the lipid profile between normal tissues, 
carcinoma associated stroma and carcinoma tissue, the m/z values which presented the changes 
with the highest significant between the different tissue types were used to plot the intensities 
distribution across all samples.  
PA was a class of phospholipids with their molecular species consistently higher in the 
tumour tissue and its associated stroma compared to both normal tissue types, demonstrated in 
Figure 3.3.15 and also in the previous Figure 3.3.3 with the different ion distributions 
presented.  
PA class is called the mother of all phospholipids as it is an essential class for membrane 
phospholipid biosynthesis. The conversion of PA to DAG and cytidine diphosphate 
diacylglycerol (CDP-DAG) are the two main arms of the phospholipid pathway, where DAG 
can precede PC and PE (Kennedy pathway), and CDP-DAG can precede PG, PI and PS (CDP-
DAG pathway). Furthermore, PA also plays a critical role as lipid second messenger that 
regulates several proteins implicated in the control of cell cycle progression, cell growth and 
survival, as for example the protein kinase mTOR (mammalian/ mechanistic target of 
rapamycin) activity [171]. For the cells to proliferate at the exceptional rate observed in cancer 
they need to synthesise phospholipids for the membrane accordingly. PA is crucial for 
phospholipid synthesis in cancer, as well as the non-controlled cell cycle progression, cell 
growth and survival, demonstrating their importance in the cancer metabolism [67, 171].  
In different metabolic studies the changes of phospholipids are also demonstrated, as it 
is the analysis of serum by Shan et al [83]. They demonstrated that, not just LPAs but also both 
PEs and LPCs play an important role in ovarian cancer diagnosis. Comparing to our study, the 
two PEs PE (P-36:5) and PE (P42:7) also show higher intensities in tumour tissue compared to 
the carcinoma-associated stroma and both control tissues. A gradual increase of PE (38:6), PE 
(40:3) and PE (42:6) are also observed from normal ovary to carcinoma-associated stroma to 
tumour. The changes on these PE species in the tumour tissue compared to normal, reinforce 
the importance of PE class in for ovarian cancer metabolism, not just in serum but also in tissue. 
In depth analysis of the role of PA in cancer, as well as other lipid classes are going to be further 
explored in chapter five.  
  
 
Figure 3.3.15. Box plots of different lipid species from five phospholipid and sphingolipid classes: phosphatidic acid (PA), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS) and ceramide (Cer) 
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In conclusion, this study reinforces the potential of DESI-MSI to a diagnostic 
application, with the example of ovarian cancer samples. Different EOC types, as well as 
different tissue types including tumour tissue and the surrounding stroma can be characterised 
and differentiated by DESI-MSI based on their lipidome. This technique shows great potential 
for tissue characterisation and assignment, complementing the classical histopathology for 
cancer diagnosis.  
 
 
 
  
Chapter 4  
Optimization of targeted MS methods 
for the analysis of phospholipids and 
sphingolipids 
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4. Optimization of targeted MS methods for the analysis of 
phospholipids and sphingolipids   
 
Lipids are the key molecules covered by the DESI-MS method used, particularly the 
classes of phospholipids and sphingolipids. To date, the analysis of these lipid classes is 
routinely performed using LC-MS [96, 102, 103]. As such, a targeted LC-MS method for the 
phospholipids and sphingolipids most frequently detected in a DESI-MSI spectrum was 
developed. The goal of this method is to demonstrate how robust DESI-MSI is for the analysis 
of lipids. Targeted approaches are still missing regarding DESI-MSI, one of the reasons why 
LC-MS is still the preferable technique. In the second part of this chapter it will be introduced 
the DESI source with a triple quadrupole instrument as a new possibility for simpler and faster 
DESI-MSI analysis.  
 
4.1. LC-MS method for phospholipids and sphingolipids   
 
4.1.1. Introduction  
 
Mass spectrometry has been a fundamental tool for the characterization of the lipidome 
in the past years. Different approaches have been developed for the analysis of lipids, this very 
diverse and complex class of metabolites. Shotgun lipidomics is one approach which consists 
of the direct injection of the sample into the mass spectrometer providing a large amount of 
data for various sample types. In this approach the separation is achieved inside the mass 
spectrometer dependent of the mass and specific ionization/adduct formation properties of each 
lipid class [172]. This technique is fast, robust and a vast number of molecules are detected at 
the same time [173]. However, this type of complex sample / data can also be a challenge, as 
not all molecules ionise with the same efficiency, allowing competition between molecules 
during the ionisation process. As such, ion suppression and ion enhancement effects cannot be 
avoided for the lipid species with low abundance.  
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Another approach uses a chromatographic pre-separation technique for the lipid 
extracts, providing advantages in the ion suppression and increasing the detection of less 
abundant lipids. Moreover, the separation techniques frequently used to obtain a 
chromatographic lipid profile are: TLC, LC, GC and capillary electrophoresis (CE) [96, 97, 
100]. LC is the chromatographic technique more commonly used in lipidomics, with three main 
types: hydrophilic interaction liquid chromatography (HILIC), normal phase chromatography 
(NP), and reversed phase chromatography (RP).  
In a RP-LC, lipids are separated based on their hydrophobicity, which means according 
to their hydrophobic part, the fatty acyl chains. As such, the chromatographic separation is 
mainly driven by the number of double bonds and the length of FA chains [174]. The NP and 
HILIC methods are precisely the opposite, the separation of lipids is driven by the polar head, 
with little contribution of fatty acid (FA) chains [175].  
As already mentioned in chapter one, the analysis of lipids can also be divided in 
targeted lipid profiling and non-targeted lipidomics [100]. For non-targeted lipidomics a 
number of different MS functions / scan modes are used to achieve the lipid profile. Full scan 
mode is the most common used function for non-targeted methods, as it detects all ions in a 
selected m/z range. Product ion scan, also known as daughter ion scan or MS/MS, follows the 
full scan mode for structural elucidation and identification of certain molecules of interest. 
Precursor ion scan and neutral loss scan modes are the two other popular acquisition modes in 
lipidomics, where the first function scans all the precursor ions which contain a selected 
fragment, and the second function scans all the precursor ions which always loses a specific 
mass when fragmented.  
The high-resolution mass spectrometers (TOF or FTMS analysers) operating in full 
scan mode are the instruments of choice for non-targeted lipidomic approaches. However, due 
to the complexity of this family of compounds, a more targeted and quantitative approach 
sometimes is preferable. Targeted lipid profiling is generally carried out using SRM or multiple 
reaction monitoring MRM acquisition mode on triple quadrupole instruments [102, 103].   
As such a targeted LC method was developed in order to identify and semi-quantify the 
lipid species detected by DESI-MSI, particularly the subclasses of phospholipids and 
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sphingolipids, giving the possibility to analyse these molecules more in depth. A triple 
quadrupole instrument was used to target the phospholipid classes, using the same concept as 
for a shotgun lipidomic approach: targeting the different polar head groups characteristic of 
each phospholipid class. To separate and target the specific molecular species in each lipid 
class, RP chromatography was used to separate according to the carbon chain length and 
saturation composition of the different combinations of fatty acids.  
 
4.1.2. Methods  
 
Materials  
 
The standards used for the development of the method were acquired from Avanti Polar 
Lipids Inc.: PA class extract (Egg, Chicken), PC class extract (Egg, Chicken), PE class extract 
(Egg, Chicken), PI class extract (Liver, Bovine), SM class extract (Milk, Bovine), Cer class 
extract (Brain, Porcine) and PS class extract (Soy). The standards used as internal standards 
were also form Avanti Pola Lipids: PC (15:0/15:0), PC (23:0/23:0), LPC (15:0), LPC (17:0), 
Cer (d18:1/17:0), PE (15:0/15:0), PE (16:0-d31-18:1), PS (17:0/17:0) and PI (16:0-d31-18:1). 
The standards were dissolved in isopropanol in a stock solution of 0.1mg/mL. Prior to analysis, 
the stock solutions were diluted to 0.01 mg/mL. 
UPLC grade solvents were used for both sample preparation and LC system, including 
methanol, chloroform, isopropanol, acetonitrile and water (Sigma-Aldrich Company Ltd, 
Dorset, UK). UPLC-ESI-MS was performed on an Acquity UPLC system (Waters Ltd. Elstree, 
U.K.) coupled to a XEVO-G2S-QTOF mass spectrometer (Waters Ltd., Manchester, U.K.) for 
initial method development and characterization of standards. Secondly the XEVO TQ-S mass 
spectrometer (Waters Ltd., Manchester, U.K.) was used for all following method development 
and quantitative analyses.  
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Sample preparation  
 
For tissue sample preparation an organic extraction based on the Blight and Dyer 
method was applied [99, 176]. All samples were weighted to normalize final resuspension. The 
first step consisted in producing a homogenate from the tissue. For this purpose, the tissue was 
placed in 2mL tubes with 1.5 mm zirconium beads (Sigma-Aldrich Company Ltd, Dorset, UK) 
and 1mL of ammonium-acetate buffer 0.1% (w/v). For the homogenisation, the tubes were 
placed into a bead beater (Precellys Homogeniser, USA) for 4 cycles of 40sec at 6500 Hz. The 
homogenate was transferred into new glass tubes to start the organic extraction.  
For the organic extraction 3.75 mL chloroform / methanol 1:2 (v/v) were added to 1 ml 
of sample, vortexed, and incubated on ice for 30 min. Then, an additional volume of 1.25 mL 
chloroform and finally 1.25 mL water was added. At the same time as the sample preparation, 
a blank tube with exactly the same quantities was prepared (sample replaced by 1 mL water). 
Following vigorous vortexing, samples and blanks were centrifuged at 150 g for 10 min to 
obtain a two-phase system: aqueous top phase and organic bottom phase with chloroform from 
which lipids were obtained.  
The organic phase was washed with the blank aqueous phase to ensure no residual 
original aqueous phase was present in the extracts. The blank organic phase was used to wash 
the aqueous phase to ensure the maximum recovery of lipids as possible from the sample. The 
clean organic phases were collected into a new glass tube, dried in nitrogen flow and stored at 
-80oC. Prior to LC-MS analysis, the samples were resuspended in 1 mL per 10 mg of tissue of 
a previously prepared solution of isopropanol / acetonitrile 1:1 (v/v). containing  the internal 
standards stated previously at a concentration of 0.1 µg /mL for the LPC (15:0), LPC (17:0) 
and Cer (d18:1/17:0), 2 µg/mL for the PS (17:0/17:0) and PI (16:0-d31-18:1), 3 µg/mL for the 
PE (15:0/15:0) and PE (16:0-d31-18:1), and finally 8 µg/mL for the PC (15:0/15:0) and PC 
(23:0/23:0).  
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LC-MS starting conditions  
 
The National Phenome Centre uses a reverse phase LC-MS method for their lipid 
profiling studies with a time run of less than fifteen minutes, which was used as a starting point 
for the development of these targeted assay. The method was performed in an Acquity BEH 
C8 column (1.7 µm 2.1 x 100mm) at a temperature of 55 oC, with the chromatographic method 
described below in Table 4.1.1. 
 
 
Table 4.1.1. LC gradient from lipid reversed-phase UPLC-MS method performed in a C8 column 
Time(min) Flow Rate %A %B Curve 
Initial 0.600 99.9 0.1 Initial 
0.10 0.600 99.9 0.1 6 
2.00 0.600 70.0 30.0 6 
11.50 0.600 10.0 90.0 6 
12.00 1.000 0.1 99.9 6 
12.50 1.000 0.1 99.9 6 
12.55 0.900 99.9 0.1 6 
12.65 0.800 99.9 0.1 6 
12.75 0.700 99.9 0.1 6 
12.85 0.610 99.9 0.1 6 
12.95 0.600 99.9 0.1 6 
14.60 0.600 99.9 0.1 6 
 
 
The composition of the mobile phase A was water / isopropanol / acetonitrile (50:25:25 
(v/v)) with 5mM ammonium acetate, 0.05% of acetic acid and B was isopropanol / acetonitrile 
(50:50 (v/v)) with 5 mM ammonium acetate and 0.05% acetic acid. The mobile phase A was 
optimized with different concentrations of phosphoric acid, from 0 to 20 µM for improvement 
of peak shape in some PL classes. The injection volume was 5 µL. The run time in the 
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chromatography was optimized to focus on elution times of the phospholipids and 
sphingolipids of interest.  
 
Mass spectrometry was performed in both positive and negative ion modes (ESI+ and 
ESI-) depending on the lipid class. The instrumental parameters used are described in Table 
4.1.2. The cone voltage, collision energy and scan duration were optimized together with the 
optimization of the different functions (neutral loss, precursor ion scan and MRM transitions). 
The optimization of collision energies and cone voltages for the different MRM transitions for 
PL representative of each class was performed with the function of the Waters MassLynx 
software (Intellistart) as well as manually. The mass range targeted in the different functions 
was also optimized to characterize the respective lipid class.  
 
Table 4.1.2. MS parameters of the initial UPLC-MS method using a XEVO-G2S-QTOF mass 
spectrometer 
 positive ion 
mode 
negative ion 
mode 
Capillary voltage 3 kV 3 kV 
Source temperature 150
o
C 150
o
C 
Desolvation temperature 500
o
C 500
o
C 
Desolvation gas flow 200 L/h 800 L/h 
Cone gas flow 150 L/h 150 L/h 
 
 
4.1.3. Results and Discussion  
 
4.1.3.1. Standards evaluation and chromatography optimization  
 
Seven different phospholipid and sphingolipid class mixtures (PC, PE, PA, PI, PS, SM 
and Cer) were acquired for the development of a targeted LC-MS method. The standards 
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mixtures were first analysed by direct infusion in a QTOF instrument to discern the different 
molecular compounds in each one of the mixtures. Still using a QTOF instrument, the 
commercial mixtures were then run separately at a concentration of 0.01 mg/mL with the initial 
LC method conditions described in the methodology (Table 4.1.1). With this analysis it was 
possible to complement the molecular information previously obtained with the retention time 
of each molecular specie (Figure 4.1.1).   
 
 
Figure 4.1.1: Base peak intensity (BPI) of all the lipid classes overlaid. The profiles were acquired in 
both positive and negative ion mode. Seven different lipid class mixtures acquired by reversed-phase 
UPLC-MS method using a XEVO-G2S-QTOF mass spectrometer performed in a C8 column  
 
The m/z values of the lipid species identified in the different lipid mixtures previously 
by direct infusion were used to analyse and detect from the corresponding chromatogram 
performed in the LC-MS analysis. With the molecular ions identified and retention times 
discovered, all information needed to start the targeted method was accomplished, as shown in 
Figure 4.1.2. As we can see, the peaks in the extracted chromatograms display a decent shape 
and retention. The less resolved peak shape was presented by PI class, one complex 
phospholipid with an inositol head group [177].  
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PS and PA class presented a slight tailed shape in some of the chromatograms. In order 
to improve the tailing of PS and PA peaks present in these conditions, phosphoric acid can be 
added to the mobile phases, as described in the literature [178]. It was also tested in this study 
different concentrations of phosphoric acid added to the mobile phase A (0 to 20µM) and its 
impact on the peak shape. We can observe in Figure 4.1.3 that increased concentrations of 
phosphoric acid reduces significantly the tailed shape of PS 17:0/17:0 species. 5 µM of 
Figure 4.1.2. Extracted ion chromatograms of all the compounds identified in the seven lipid classes mixtures in the 
positive (top) and negative (bottom) ion mode. Lipid class mixtures acquired by reversed-phase UPLC-MS method using a 
XEVO-G2S-QTOF mass spectrometer performed in a C8 column 
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phosphoric acid was the concentration chosen, as it was a good compromise between 
acceptable peak shapes and LC instrumentation durability as well as possible adduct 
formations.  
 
 
The chromatographic run was optimized in order to achieve: a) short analysis times, b) 
separation of the targeted lipids, c) similar conditions for all the classes of lipids to be simpler 
to use. For this purpose, the starting composition of the method as well as the gradient were 
tested. The lipids of interest did not appear in the first 2 minutes of the run, where the gradient 
goes from 99% of mobile phase A to 85%. As such, the composition of initial conditions did 
not need to be 99% of A but 85%.  
After optimization, the chromatographic method had a turnaround time of 10.5 min as 
shown in Table 4.1.3.  
Figure 4.1.3. Optimization of the tailed shape of PS 17:0/17:0 with the 
increase concentration of phosphoric acid addition in the mobile phase A. 
The first graph shows the chromatogram of this PS with 20 µM phosphoric 
acid, the second with 10 µM and the third no phosphoric acid.  
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Table 4.1.3: Chromatographic run with the final times, flow rates and solvent percentages  
Time(min) Flow Rate (mL/min) %A %B Curve 
Initial 0.600 85.0 15.0 Initial 
0.10 0.600 85.0 15.0 6 
1.00 0.600 70.0 30.0 6 
9.00 0.600 20.0 80.0 6 
9.10 0.750 0.1 99.9 6 
9.60 0.750 0.1 99.9 6 
9.70 0.600 85.0 15.0 6 
9.80 0.600 85.0 15.0 6 
10.50 0.600 85.0 15.0 6 
 
 
To continue improving the analysis of these lipids, the MS parameters were also 
optimized. With this reversed-phase chromatography we can observe that the different lipid 
classes elute in similar run time ranges, with a clear separation of the different molecular 
species inside each class as it is described in the literature [103] and we demonstrated before 
(Figure 4.1.2). A longer gradient could improve the separation between the classes but would 
also increase the run time. An alternative to distinguish the lipid classes from each other is the 
use of a triple quadrupole mass spectrometer [179]. This instrument is able to perform neutral 
loss and precursor ion scans, which allow the separation of the phospholipid classes by the 
characteristic head group as described in Table 1.3.2 in chapter one.  
For the class of PC, SM and LPC, the best function to operate was the precursor ion 
scan targeting the fragment of 184 Da in the positive ion mode, which corresponds to the 
choline head group [180]. SM and PC classes have their mass range similar but these molecules 
are easily distinguishable due to their structural differences on the linkage between the 
phosphate group and the fatty acids, where the SM has a sphingosine backbone. As such, the 
two nitrogen atoms in this molecule makes the m/z values of the respective ions always odd 
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numbers, the opposite of PC class, where just one nitrogen is present and m/z values always 
even numbers [24]. The PE and lysophosphatidylethanolamine (LPE) classes were detected 
using a neutral loss scan of 141 Da, corresponding to the loss of ethanolamine head group in 
positive ion mode. For the ceramide class, the fragment of selection was the precursor ion scan 
of 264 Da in positive ion mode, corresponding to the sphingosine backbone. In the negative 
mode we were able to detect 3 classes with 2 different functions. For the PI class, a precursor 
ion scan of 241 Da (inositol) was used and for the PA and PG classes the precursor ion scan of 
153 Da. PS class was analysed by neutral loss of 87 Da in negative ion mode, corresponding 
to the loss of the serine head group, but surprisingly the chromatogram did not show the results 
described in the literature [102, 180] as we can see in Figure 4.1.4. These findings suggest that 
the fragment corresponding to the loss of serine in the PS species appears with very low relative 
abundance.  
 
 
4.1.3.2. MS parameters optimization  
 
Optimization of MS parameters were first done with direct infusion combined with 
constant LC flow rate (0.6 mL/min) on the triple quadrupole instrument with neutral loss and 
precursor ion scan functions suitable for each individual class.  
Figure 4.1.4. Comparison between chromatograms of MS mode and neutral loss 
mode function for the commercial PS extract used in the method optimization 
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The cone voltage and collision energy were carefully optimized using the Waters 
MassLynx software tool IntelliStart and manually. An example of this optimization is the 
Figure 4.1.5 with the lipid PE (38:4). This figure shows the impact on the chromatogram of a 
gradual increase of energy for both parameters CE and CV.  
 
 
The Figure 4.1.5 shows the results of the ramp produced by the software for the collision 
energy (Figure 4.1.5-I.a) and cone voltage (Figure 4.1.5-II.d), which suggests 34V and 12V 
respectively. In Figure 4.1.5-I.b-c and II.e-f shows the same ramp was done manually and with 
longer scans. For the cone voltage the first 20 V showed the best total ion count. For the 
collision energy we evaluated the effect of the energy ramp on the precursor ion and the 
Figure 4.1.5. Optimization of collision energy (I) and cone voltage (II). Ramps performed using the 
Intellistart tool in MassLynx (a and d) and manually (I.b-c and II.e-f), slowly increasing the values in 
the tune page 
 
107 
 
fragment ion. The optimal collision energy for the chromatogram of both the precursor and the 
fragment was between 25 and 30 V.  
The parameters optimized using combined direct infusion were confirmed with the LC-
MS system, such as flow rate and solvents used, as well as the capillary voltage, source offset, 
source temperature, desolvation temperature and scan duration. The final parameters used in 
the method are describe in Table 4.1.4.  
 
Table 4.1.4: Mass spectrometric acquisition parameters for each class of lipids (LPC - lysophosphatidylcholine, PC-
phosphatidylcholine, SM- sphingomyelin, LPE- lysophosphatidylethanolamine, PE- phosphatidylethanolamine, 
Cer- ceramide, PI- phosphatidylinositol, PG- phosphatidylglycerol, PA- phosphatidic acid) 
 LPC/PC+SM LPE/PE Cer PI PG+PA 
Capillary (kV) 3 3 3 3 3 
Cone (V) 20 20 20 40 20 
Source Offset (V) 50 50 50 50 50 
Source Temperature 
(°C) 
150 150 150 150 150 
Desolvation 
Temperature (°C) 
500 500 500 500 500 
Cone Gas Flow (L/Hr) 150 150 150 150 150 
Desolvation Gas Flow 
(L/Hr) 
200 200 200 800 800 
Collision Gas Flow 
(mL/Min) 
0.15 0.15 0.15 0.15 0.15 
Nebuliser Gas Flow 
(Bar) 
7 7 7 7 7 
Scans in function: 2422 2422 2422 1935 2032 
Scan duration (sec): 0.25 0.25 0.25-0.225 0.3 0.225 
Start and End 
Time(mins): 
0.00 to 10.50 0.00 to 10.50 
0.00 to 
10.50 
0.00 to 
10.50 
0.00 to 
10.50 
Ionization mode: ES+ ES+ ES+ ES- ES- 
Function type: 
Precursor of 
184.00 
Neutral Loss 
of 141.00 
Precursor 
of 264.00 
Precursor 
of 241.00 
Precursor of 
153.00 
Mass range: 400 to 900 400 to 950 300 to 800 500 to 950 350 to 850 
Collision Energy: 28 18 25 44 32 
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4.1.3.3.From standards to biological samples 
 
An organic extraction (Blight and Dyer based extraction) of food grade pork liver tissue 
was performed and tested with this method. A comparison of chromatograms between the pork 
liver tissue and the class extracts from Avanti Polar Lipids Inc. was made and the analysis of 
the most prominent lipids was accessed in (Figures 4.1.6-11).   
 
 
 
Figure 4.1.6. Chromatograms with the corresponding MS spectrum of precursor ion scan of 184 function, 
both in the standards and pork liver extract 
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As shown in Figures 4.1.6 and 4.1.7 PC and PE class had a very satisfactory 
chromatogram. In the first part of the run we can even detect some lysophospholipids, small 
phospholipids with just one fatty acid tail.  
 
 
 
Although the class demonstrated a slight decrease in signal intensity when applied to 
the analysis of the organic extract, the ceramide class shows a very clear peak shape and a 
similar representation to the standard analysed previously.  
Figure 4.1.7. Chromatograms with the corresponding MS spectrum Neutral loss scan of 141 function, both 
in the standards and pork liver extract 
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Figure 4.1.8. Chromatograms with the corresponding MS spectrum of precursor ion scan of 264 function, both in the 
standards and pork liver extract 
Figure 4.1.9. Chromatograms with the corresponding MS spectrum of precursor ion scan of 241 function, both in the 
standards and pork liver extract 
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PI class is known to be one of the most difficult phospholipid classes to analyse due to 
their low abundance and complex structure containing an inositol moiety [24, 25]. 
Interestingly, comparing both standards and organic pork liver extract analysed in negative ion 
mode, this class demonstrated comparable and reproducible chromatogram and spectra upon 
the analysis of precursor ion scan of the fragment 264Da.  
However, the PG and PA classes did not produce satisfactory chromatograms when 
analysing the organic extract (Figure 4.1.10). The chromatogram was not clear and the signal 
to noise ratio was too low. The low sensitivity of these two classes can be due to different 
factors, as their low abundance in the cell. PA class is constantly in transition, being used to 
synthesise more complex phospholipids [31]. PGs are more common in prokaryotic cells, being 
in lower abundance in the eukaryotic cells, more centralized in the mitochondria [31] or 
produced as surfactants in the lung [181].  
 
 
Figure 4.1.10. Chromatograms with the corresponding MS spectrum of precursor ion scan of 153 function, both in the 
standards and pork liver extract 
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Other organic extracts were also tested to evaluate the applicability of the method in 
different sample types. An example was the organic extract of ovarian cancer tissue and normal 
ovarian tissue, where the lipidome investigation can bring us new insights about the lipid role 
in cancer.  
At this point of the study some more experiments related to the PS class already on the 
ovarian cancer samples were tested and it was possible to analyse this class in positive ion 
mode with the neutral loss of 185 Da, corresponding to the phosphoserine head group. With 
this function the class gave a very clear and defined profile (Figure 4.1.11), suggesting that the 
loss of 185 Da fragment (the serine together with the phosphate group) is characteristic and 
present with high abundance with these conditions.  
 
The parameters used to analyse this class are shown in Table 4.1.5. When compared to 
the liver organic extract, it also demonstrates a good intensity chromatogram and representative 
spectrum from PS class. 
 
Figure 4.1.11. Comparison of MS spectrum with the neutral loss of 185 function of the standard mixture 
corresponding to the PS class. Application of this function in an ovarian cancer organic extract. 
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Table 4.1.5. MS parameters used for the neutral loss function of 185 function, in positive ion mode, 
characteristic of the PS class 
Capillary (kV) 3 Nebuliser Gas Flow (Bar) 7 
Cone (V) 20 Scans in function: 2464 
Source Offset (V) 30 Scan duration (secs): 0.25 
Source Temperature (°C) 150 Start and End Time(mins): 0.00 to 10.50 
Desolvation Temperature (°C) 350 Ionization mode: ES+ 
Cone Gas Flow (L/Hr) 150 Function type: Neutral Loss of 185 
Desolvation Gas Flow (L/Hr) 650 Mass range: 400 to 900 
Collision Gas Flow (mL/Min) 0.25 Collision Energy: 20 
 
The PC class chromatogram was saturated, as this class has higher abundance compared 
to the other phospholipid classes, specially seen in positive ion mode. To overcome this 
problem the sample could be diluted but that implies diluting all the other lipid species or 
having another vial / injection per sample. The other solution is to optimize the collision energy 
in the method for the signal not to be ideal and more comparable to the signal / abundance in 
the spectra of the other phospholipid classes. The collision energy chosen was 100V, which 
enabled the analysis of all these lipid classes in the same vial with the same concentration. 
To improve the sensitivity and include as many functions as possible in a single run, 
we transformed each function into different MRM transitions, always targeting the 
phospholipid head group as in the previous functions of neutral loss and precursor ion scan. 
For each class a method was created in the TargetLynx application tool in the Waters 
MassLynx software, able to integrate the peak areas / transitions of interest.  
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Table 4.1.6. Phosphatidylcholine (PC) species targeted together with their identification, retention 
time transition, collision energy and cone voltage in positive ion mode.  
m/z Lipid ID RT Transition  
732.55 PC 16:0/16:1 5.82 732.6->184 
734.57 PC 16:0/16:0 6.32 734.6->184 
758.57 PC 16:0/18:2 5.97 758.6->184 
760.59 PC 16:0/18:1 6.49 760.6->184 
782.57 PC 16:0/20:4 5.95 782.6->184 
784.59 PC 18:1/18:2 6.1 784.6->184 
786.60 PC 18:1/18:1 6.65 786.6->184 
788.62 PC 18:1/18:0 7.15 788.6->184 
806.57 PC 16:0/22:6 5.75 806.57->184 
806.57 PC 18:2/20:4 5.55 806.6->184 
808.59 PC 18:1/20:4 6.09 808.6->184 
810.60 PC 18:0/20:4 6.63 810.6->84 
834.60 PC 40:6 6.44 834.6->184 
 
 
The precursors to target were previously selected from the analysis made in both the 
standards, the liver and ovarian extract, summarized in Table 4.1.6 of the PC class as an 
example. For the lipids that different fatty acid combinations were not clear in the 
chromatogram, the integration was performed with the area of the meaningful peaks and the 
name was still mentioned as the sum of both fatty acids. The other class tables as well as an 
example of peak integration are shown in supplementary information.  
The two lipid species used for the PC class were PC (15:0/15:0) and PC (23:0/23:0). 
These molecules, as they have odd chain fatty acids, they are not present in human tissues, 
making them ideal to use as internal standards when analysing the PC class.  
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Figure 4.1.12 demonstrates the calibration curve of these two compounds with four 
replicates. From these calibration curves it was possible to calculate the coefficient of variation 
(CV) for these lipids and evaluate if all concentrations have the CV of lower or equal than 25%. 
PC 15:0/15:0 did not show a sufficient CV for the first two concentrations (0.064 µg/mL and 
0.128 µg/mL). For the PC (23:0/23:0), it did not show a satisfactory coefficient of variation for 
the last 3 concentrations used. As such, the PC (15:0/15:0) was chosen to be the internal 
standard for the PC class.  
The graph in Figure 4.1.13 illustrates the ratio between the intensity of the standard and 
the background, allowing the calculations of the limit of detection (LOD) and limit of 
quantification (LOQ). The lowest concentration with a ratio higher than 3 is considered the 
LOD and lowest concentration with a ratio higher than 10 is consider the LOQ. The linear 
range for this standard is between 0.256 µg/mL to 4.096 µg/mL, as the detector showed a linear 
response inside these concentrations and it is within the limit of quantification defined before.  
Figure 4.1.12. Evaluation of the calibration curve using two PC species, PC (23:0/23:0) and PC (15:0/15:0) 
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Figure 4.1.13. Evaluation of the limit of detection and quantification for the PC (15:0/15:0) 
 
 
4.1.3.4. Application to study samples  
 
The targeted method for phospholipids and sphingolipids was applied in a clinical 
cohort of high grade serous ovarian carcinoma. The results of the analysis will be discussed in 
chapter five. In this part of the study it will be demonstrated how robust and reproducible the 
method is analysing the different quality control samples acquired in parallel with the study 
samples. For this purpose, one lipid internal standard per class was used, as described in Table 
below (table 4.1.7).  
For the PC class, the transitions of 13 PCs were achieved, as described in Table 4.1.6, 
together with the PC (15:0/15:0) as internal standard.  
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Table 4.1.7. List of internal standards tested for the application of the LC-MS method  
class ID m/z 
Concentration 
used 
Mean area in all 
samples and QC SD CV % 
PC 
PC (15:0/15:0) 706.54 
8 µg/mL 
239558.65 37786.43 15.8 
PC (23:0/23:0) 930.79 461018.54 184182.18 40.0 
LPC 
LPC (15:0) 482.32 
0.1 µg/mL 
352013.20 28313.43 8.0 
LPC (17:0) 510.36 272301.99 26511.76 9.7 
Ceramide Cer (d18:1/17:0) 552.54 0.1 µg/mL 1275.24 286.43 22.5 
PE 
PE (15:0/15:0) 664.49 
4µg/mL 
4247293.86 594762.05 14.0 
PE (16:0-d31-18:1) 749.73 261864.22 163099.27 62.3 
PS PS (17:0/17:0) 764.54 2 µg/mL 23219.30 6891.62 29.7 
PI PI (16:0-d31-18:1) 866.73 4 µg/mL 3296.24 658.20 20.0 
 
 
The stability of these internal standards was evaluated across all runs, being able to see 
how stable and reproducible the method was across all runs. With the known concentration 
used for the internal standard, the coefficient of variance was calculated based on the mean of 
the internal standards across all samples and quality control (QC-pool of all samples analysed 
in between the different samples). Figure 4.1.14 also illustrates the relative abundance of the 
PE 15:0/15:0 as an example, across all runs of the study, including samples and QC.  
 
 
Figure 4.1.14. Integrated area of the internal standard PE (15:0/15:0) across all QC runs from this 
study.  
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There was sufficient low variation according to the days of the runs. Unfortunately, four 
samples were not valid to use, as we can observe in Figure 4.1.14 for the PE class. These 
samples are highlighted in Figure 4.1.14 and, when analysing the chromatogram, the signal 
was very low or almost inexistent in these runs. The absence of signal happened across all IS, 
suggesting the error happened during the preparation or injection of the vial corresponding to 
that samples.   
In Table 4.1.7 we can also observe the mean of all areas integrated of internal standards 
across all samples, as well as the standard deviation and the CV. The CVs of all internal 
standards demonstrate the reproducibility of this method, as they are all below 30%, with the 
exception of the PC (23:0/23:0) and PE (16:0-d31-18:1).  
 
Figure 4.1.15. a) Average of the ion peak areas integrated for PI and LPC class in all quality control (QC) 
samples analysed across the run. b) Overlaid chromatograms of all QC runs for two different classes as an 
example, the PI and LPC class. c) Average with coefficient variance of all peaks from the class PI and LPC  
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The next evaluation step performed was related to the stability of the measurements 
across the runs. The LPC and PI class are shown as example in Figure 4.1.15. The area of all 
peaks integrated across the QCs was compared, demonstrating low variance, with a CV 
between 5 and 8 for the LPC class, and between 11 and 37 for the PI class.   
 
The Figure 4.1.15 illustrates the similarity between the chromatograms across the QCs 
analysed with the method.  
With the method development performed, it was possible to compare qualitatively the 
changes observed in these lipid profiles. Ratios of the different m/z integrated areas with the 
areas of the internal standard were used to calculate relative abundance of the lipid species.  
For future work an absolute quantification can be performed with a wider range of 
standards. Phospholipids within the same class have linear ionization response, as already 
described in the literature [182]. Based on this principle it would be possible to create a 
calibration curve not just related to the concentration but also related to the fatty acid chain 
length. Measuring between five and six phospholipids per class with different carbon chain 
lengths in different concentrations it would be possible to calculate the ionization response 
inside each class. As internal standards, one phospholipid per class with odd chain fatty acids 
were chosen as they are not common in the human body. 
These analyses presented here can already illustrate how reproducible and stable the 
method is, bringing a huge potential for the quantification of these lipid species.  
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4.2. DESI-MSI as a targeted tool  
 
4.2.1. Introduction  
 
MSI has been gaining importance in the past decades due to its ability to provide not 
only the molecular composition of a given sample but also the spatial distribution of its 
analytes. When applied to tissue samples, it allows characterization of different tissue types 
based on their molecular composition and distribution [131].  
The utility of DESI-MSI for tissue imaging has been demonstrated for various tissue 
types and pathologies. As described in the previous chapter, various types of cancer have been 
characterized, such as colorectal cancer [137], breast cancer [139], lymph node metastases 
[143], and brain tumours [141]. These studies illustrate how DESI-MSI can overcome some 
problems linked to diagnosis and prognosis of cancer by complementing and supplementing 
classical histology.  
The majority of the applications reported thus far, however, are qualitative and based 
on untargeted profiling. The lipidomic profile provided by this approach is very useful both for 
tissue identification and in order to understand and investigate the lipid metabolism in different 
tissue types. Nevertheless, the data from these analyses can achieve easily hundreds if not 
thousands of megabytes, making it difficult to process and analyse. Furthermore, for routine 
clinical application, a much simpler, faster and less expensive technique would be ideal.  
There have been studies where DESI was used as a quantification method [183], but 
using a complex instrument and full scan mode for quantification and looking at specific drugs 
in rat brain rather than endogenous molecules. Others have combined this ambient ionization 
technique with the sensitivity and MRM capability of a triple quadrupole instrument for 
quantification, but the studies did not take in account the spatial distribution of molecules, one 
of the major strong points of DESI-MSI [184].  
In this chapter, a DESI stage was coupled with a triple quadrupole instrument to allow 
a semi-targeted approach for tissue imaging and tissue characterization.  
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4.2.2. Methods  
 
Method development was performed using food-grade pork liver and the applicability 
of the method was then demonstrated using human high grade serous ovarian carcinoma 
samples (Tissue Bank sub-collection number GYN/HG/12/060) as the previous study. Fresh 
frozen samples were cryo-sectioned at 10 µm thickness, mounted onto glass slides and stored 
at -80 oC until DESI-MS analysis. After DESI-MSI, sections were stained using haematoxylin 
and eosin (H&E) for histopathological annotation, the same procedure as for the previous 
chapter. 
For the lipid profile analysis, an Exactive Fourier transform Orbitrap mass spectrometer 
(Thermo Scientific, Bremen, Germany) was used controlled by XCalibur 2.1 software and 
operated in positive ion mode. The mass spectrometer was coupled to a home-built DESI ion 
source with also a home-built sprayer [139]. 
The targeted experiments were performed on a Xevo TQ-S (Waters Corporation, 
Milford, MA) coupled to a DESI 2D sample stage from Prosolia Inc. (Indianapolis, IN, USA) 
with the commercial sprayer from Waters [185]. 
DESI-MS images were acquired at a nominal pixel size of 100 µm and an electrospray 
voltage of 4.5 kV. DESI-TQ data was acquired with a solvent flow rate of 2 µl/min 
(methanol/water, 95:5) and a nitrogen inlet pressure of 6 bar. For the DESI-Exactive 
experiments, a flow rate of 1.5 µl/min was used with a nitrogen inlet pressure of 7 bar.  
The high resolution profiling MSI data was converted to imzML format using imzML 
Converter (V1.1.4.5) [166] and imported into MATLAB (R2014a) for pre-processing and 
analysis using an in-house Matlab toolbox [163].  
Targeted data acquired on the triple quadrupole instrument was analysed in an 
experimental software, MRMToCSVConvertor-TQ Visualiser V0.1, which allows 
visualization of individual MRM transition channels as well as different MRM functions.  
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4.2.3. Results / Discussion  
 
For DESI-MSI to be routinely used in a diagnosis level, the development of a faster, 
cheaper and simpler instrument would be the ideal setup. Furthermore, a more targeted 
approach would bring some advantages to the analysis, being more tissue / disease specific and 
less as a discovery approach. For that we combine the potential of a triple quadrupole 
instrument (TQ) for targeted analysis, and its high sensitivity for that approach, with the spatial 
information DESI source can bring us.  
 
4.2.3.1.Triple quadrupole instrument and the first MRM transitions for DESI-MSI 
 
The food grade pork liver was frozen and sectioned to be used as a test sample. The 
DESI Prosolia stage was coupled to a TQ and a full scan MS profile of a pork liver section was 
acquired (Figure 4.2.1a). An average spectrum of the tissue area was calculated in order to 
characterize the lipids found and select appropriate targets for the MRM transitions. PCs and 
other choline-related compounds are easily ionized and can be found in the majority of tissues, 
being one of the most abundant phospholipids in the cell membrane [186]. Therefore, the PC 
class as well as some species from SM class were selected and molecules of different relative 
abundances in the spectrum were targeted.  
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The next step was the optimization of different MRM transitions for choline-related 
compounds by evaluating the respective ion image. This optimization was again performed on 
pork liver sections as shown in Figure 4.2.2 where two PCs and two SMs were used for this 
purpose. These ion images were compared to the optical image of the H&E stained section and 
the lobular structure of the liver tissue could be clearly identified on the different ion images. 
Interestingly some compounds were defining more the liver lobules and others the connective 
tissue outside the lobules. For example, the SM (d34:1) as well as PC (34:1) represent quite 
clearly the portal area and the lobule boundary, while the PC (38:4) and SM (d42:3) define the 
lobules themselves.  
Figure 4.2.1. a) Average MS spectrum of a pork liver section acquired in a Xevo TQ-S and b) an 
average spectrum of an ovarian cancer section acquired in a high resolution Exactive instrument 
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4.2.3.2.Application to clinical study  
 
High grade serous ovarian carcinoma samples were used to test the capability of some 
choline related MRM transition images to characterize complex clinical tissue specimens. The 
first step was to compare the average spectrum of the pork liver tissue area calculated with the 
previous DESI-MSI profile from the high resolution instrument shown on the previous chapter 
to ensure the DESI profile in positive ion mode were similar between instruments (Figure 
4.2.1b). The data acquired in the previous chapter was also used to characterize the lipids found 
in the samples and select appropriate targets for the MRM transitions.  
The MRM transitions for the selected PC and SM species (Table 4.2.1) were then 
optimized by adjusting the collision energy and cone voltage. For all analytes, the choline head 
group was targeted, in order to capture all possible fatty acid configurations. For the protonated 
Figure 4.2.2. a) MS/MS spectrum of PC (34:1), b) H&E image and c) respective ion images od a 
pork liver section 
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adducts ([M+H]+) the transition optimized was for the fragment m/z 184, the phosphocholine 
fragment, as it was used in the LC-MS method previously described. For some lipids species, 
the sodiated adducts ([M+Na]+) with the characteristic loss of another choline related fragment 
(loss of 59Da) as more abundant. As such, for these molecules the neutral loss of these fragment 
was optimized.  
DESI-MSI-MRM images for the compounds described in Figure 4.2.3 were acquired, 
aligned with the optical images of the H&E stained sections and were annotated by a qualified 
histopathologist.  
 
Table 4.2.1. MRM transitions optimized for the ovarian carcinoma samples 
Compound  m/z MRM Adduct 
SM(d34:1) 703.57 >184 [M+H]
+
 
SM(d42:3) 811.67 >184 [M+H]
+
 
PC(32:0) 756.55 >697 [M+Na]
+
 
PC(36:4) 782.57 >184 [M+H]
+
 
PC(36:7) 798.63 >739 [M+Na]
+
 
PC(38:8) 824.65 >765 [M+Na]
+
 
 
The first sample tested had a two main tissue types: tumour and necrotic tissue (Figure 
4.2.3). There was a clear separation between the necrotic tissue and the tumour tissue based the 
abundance of the different lipids targeted. For example, PC (38:8) and PC (36:7) showed higher 
intensity on the tumour areas compared to the necrotic areas.  
 
A second sample tested was composed of tumour tissue and tumour-associated stroma 
tissue (Figure 4.2.4), which are the typical tissue types found in a serous ovarian carcinoma 
sample.  
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Interestingly, some of the ions clearly characterized the tumour areas, while others were 
more homogeneously distributed. For example, PC (38:8) and PC (36:7) were highly intense 
in the tumour areas while PC (36:4), PC (32:0) and SM (34:1) showed a more homogenous 
distribution across the tissue section.  
Figure 4.2.3. Comparison of different MRM ion images in a high grade serous ovarian 
carcinoma sample 
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Therefore, an overlaid ion image reflecting the histology of the tissue could be created 
by overlaying the summed intensities of PC(38:8) and PC(36:7) (Figure 4C, red component) 
and their ratio to the sum of the other three species (PC(36:4), PC(32:0) and SM(34:1)) (Figure 
4.2.5). This illustrates how just 1 SM and 4 PCs can characterize and separate the two different 
tissue types (stroma and tumour) found in epithelial ovarian carcinoma samples.  
 
Figure 4.2.4. Comparison of different MRM ion images in a high grade serous ovarian carcinoma 
sample 
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Figure 4.2.5. Optical image together with the ion image from the MRM transitions coloured in two 
channels 
To validate the ion distribution for the different lipid species, ion images acquired by 
the high mass resolution instrument were compared to those obtained by this low mass 
resolution approach. Figure 4.2.6 shows the comparison between the different transitions 
acquired and the respective ion image from the profiling data with five lipid species of PCs and 
SMs.  
 
 
It has to be noted that there are no specific bioinformatics tools available for the MRM 
data in contrast to the single stage DESI-MSI data acquired in the previous study. However, 
Figure 4.2.6. Comparison of specific lipids and their distributions acquired by DESI-MSI in an 
Exactive Fourier transform Orbitrap mass spectrometer (a) and DESI-MRM in a Xevo TQ-S 
instrument (b) 
a) 
b) 
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the different ion images representing the same m/z value show very good agreement between 
the two platforms, illustrating the robustness of the DESI technique across different 
instruments.  
 
Overall, by combing DESI-MS imaging with triple quadrupole mass spectrometer, it is 
possible to accomplish tissue characterization and identification of cancer tissue and stroma 
tissue using only a few selected lipid biomarkers. This targeted and selective approach allows 
the use of low-end and robust MS instrumentation, making the DESI setup smaller, simpler 
and cheaper, and strengthening its potential as a routine clinical tool, as some triple quadrupole 
instruments are European Conformity marked for IVD (in vitro diagnostics) use.  
 
   
Chapter 5  
Ovarian cancer and its lipid 
metabolism 
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5. Ovarian cancer and its lipid metabolism   
 
5.1. Introduction  
 
Lipids have been demonstrated to play essential roles in cancer, not just structurally but 
also in signalling and as an energy source. As discussed in the introduction, there is evidence 
of phospholipids as potential biomarkers for ovarian cancer [78-81]. PA and lysophospholipids 
are the phospholipids most commonly associated with ovarian cancer, especially due to their 
direct role in inflammation [67, 68, 83]. Fatty acids are another class of lipids with high 
importance in cancer development and survival, not just due to the increase of de novo synthesis 
but also their role in membrane fluidity [1].  
Although the lipidomic field has developed substantially in the last decade, we are still 
a long way away from understanding the changes in the lipid metabolism in this pathology. 
Therefore, this work examined changes in lipid metabolism in ovarian cancer. To do this, the 
lipid profiles found by DESI-MS were compared to the relevant literature data. Furthermore, 
the DESI-MS findings were validated and refined with the application of the LC-MS method 
described in chapter four, as well as the results of the immunohistochemistry experiments 
performed for the main enzymes involved in fatty acid and PL metabolism.  
 
5.2. Methodology  
 
For this chapter, complementary data analysis was performed on the data acquired in 
chapter three to better interpret the complex lipidomic data obtained by DESI-MS. All the m/z 
values were first matched with the available online databases with the following combination 
of different adducts: in positive ion mode [M+H]+, [M+Na]+ and [M+K]+ and in negative ion 
mode [M-H]-, [M+Cl]- and [M-H2O-H]
-. The database matching was performed based on the 
accurate mass and isotope patterns using Metlin [167], Lipid Maps [168] and HMDB [169]. 
The averaged and TIC normalized mass spectra obtained in the chapter three were used to 
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calculate the mean fold change (MFC) between different groups and ANOVA statistical 
analysis was performed for all annotated lipids.  
Immunohistochemistry of some key enzymes involved in phospholipid metabolism as 
well as de novo fatty acid synthesis was analysed. The remainder of the frozen tissue sectioned 
for DESI-MS was formalin-fixed and paraffin embedded to produce tissue sections for the 
immunohistochemical analysis.  
 
Table 5.2.1. Enzyme antibodies used in the study together with the supplier and parameters chosen 
for the experiment  
Antibody Supplier Clonality Cat.no 
Antigen 
Retrieval Dilution 
Fatty Acid 
Synthase (FASN) Santa Cruz 
Mouse monoclonal, 
A-5 sc-55580 EDTA 20min 100 
ATP citrate lyase 
(ACLY) Abcam 
Mouse monoclonal, 
3G8 ab118150 Citrate 20min 200 
Acetyl Coenzyme 
A carboxylase 
alpha (ACACA) 
Abcam Rabbit monoclonal, 
EPR4971 ab109368 Citrate 20min 
250 
for human 
SCD1 Abcam Mouse monoclonal, 
A-5 ab19862 EDTA 20min 200 
ELOVL1 Santa Cruz Goat polyclonal sc-54870 EDTA 40min 25 
CD36 OriGene Mouse monoclonal, 
3F4 CF500921 EDTA 20min 
1000 
for human 
Carboxylesterase 
1 (CES1) Sigma Rabbit polyclonal 
HPA012023 
100UL Citrate 20min 200 
NFkB p65 Abcam Rabbit polyclonal 
ChIP Grade ab7970 EDTA 20min 500 
Anti-PAP2A 
Antibody [Clone 
OTI1H4] 
OriGene 
mouse monoclonal 
antibody, clone 
OTI1H4 
TA506857 Citrate 20min 150 
for human 
CDS1 antibody GeneTex 
Rabbit polyclonal 
CDS1 antibody 
[C1C3] 
GTX112491 EDTA 20min 100 
for human 
PLD2 E1Y9L Cell 
Signaling 
Rabbit monoclonal 
Antibody, clone 
E1Y9L 
#13891 EDTA 20min 250 
for human 
 
 
The enzymes used were the following: FASN, ACLY, acetyl coenzyme A carboxylase 
alpha (ACACA), stearoyl-Coenzyme A desaturase (SCD1), fatty acid elongase 1 (ELOVL1), 
cluster of differentiation 36 (CD36), also known as fatty acid translocase, carboxylesterase 1 
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(CES1), nuclear factor kappa-B p65 subunit (NFkB p65), phosphatidic acid phosphatase 2a 
(PAP2A), phosphatidate cytidylyltransferase 1 (CDS1) and PLD2. All the product codes with 
the respective suppliers as well as the incubation parameters are shown in Table 5.1.1.  
The LC-MS/MS data was evaluated and univariate statistical analysis was performed 
across all lipids targeted with the method explained in the chapter three. For this data, the 
representative lipid species of each class were semi-quantified. The 68 tissue samples used 
were divided in four groups: a tumour group where the H&E analysis revealed between 90% 
and 100% of tumour cells, a stroma group, where the H&E analysis revealed between 90% and 
100% of stromal tissue, a mixed tumour group, where the samples had mixed stroma tissue and 
tumour tissue, and a control group, for the normal ovarian stroma.   
 
5.3. Results and discussion   
 
5.3.1. Lipidomic pathway analysis by DESI-MS 
 
The DESI-MS data acquired in chapter three was further analysed in order to study the 
lipidome of the different ovarian tissue types. The lipidome of the most common type of 
ovarian cancer, serous ovarian carcinoma, was studied and compared to normal ovarian stroma. 
The phospholipid and sphingolipid species identified were divided and analysed by class. The 
two most abundant main lipid classes on the DESI-MS spectrum were phospholipids and 
sphingolipids, being therefore the focus of this study.  
In negative ion mode, the intensity of the different lipid classes is more evenly 
distributed than in positive ion mode, where the PC class dominates the spectrum. Moreover, 
in positive ion mode, different lipid species can be detected as various adducts, i.e. as proton, 
sodium or potassium adducts, making the data more complex. However, the positive ion mode 
is important for studying the lipid classes ionised poorly in negative ion mode, such as DAG 
(also known as DG), triacylglycerol (TG) and the most abundant lipid class in positive ion 
mode, PC. As such, the main purpose of the positive ion mode analysis in this study is to 
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complement the information given by the negative ion mode, offering a wider range of 
molecules for the analysis.  
The percentage of ions matched with the databases for each lipid class is demonstrated 
in Figure 5.3.1 for negative ion mode and 5.3.2 for positive ion mode, together with the 
percentage of annotated species significantly different across the three tissue types analysed 
(with q-value smaller than 0.05). The second part of these two figures shows the relative 
abundance of same matched m/z values grouped per lipid class for the same tissue types. The 
relative abundances were calculated from the sum of all normalized intensities belonging to the 
m/z values matched for each individual class. With this analysis it is possible obtain the number 
of ions annotated as well as the relative abundance of these same ions, in Figure 5.3.1 for 
negative ion mode and 5.3.2 for positive ion mode, and evaluate their changes across the three 
tissue types, healthy normal ovary, tumour associated stroma and tumour from high grade 
serous carcinoma samples.  
The class with highest diversity as well as the highest relative abundance across all 
tissue types in negative ion mode is the PE class, followed by the PS class. Despite not having 
as many annotated species as the PS and PE classes, the PI class is also present at high relative 
abundance. Sphingolipids, such as SM and ceramides, are less abundant, with a lower number 
of annotated features. However, these two classes have the highest percentage altered lipid 
species with significance inside the class.  
Looking at the relative abundances of the two classes of sphingolipids, we can perceive 
a decrease of relative abundance in both tumour tissue and tumour associated stroma compared 
to normal ovarian tissue. The PS and PC classes show a slight trend in the same direction as 
the ceramide and SM classes. On the other hand, for the PI class as well as the PA class, we 
can see an increase in the relative abundance in both tumour related tissue types compared to 
normal ovarian tissue. Although not so obvious, the PG class also demonstrates the same 
tendency.  
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In positive ion mode, the PC class shows the highest diversity and also the highest 
relative abundances, in accordance with the literature [31]. The PC class is followed by the PE, 
PG and PS classes in both number of features and relative abundance. Nevertheless, the class 
with highest number of significant annotated molecular species in both modes is the PE class, 
demonstrating the importance of this class for tissue classification in this cohort. As mentioned 
before, the variability of the spectrum in positive ion mode is much influenced by the presence 
of adducts each ion can form. Nevertheless, the lipid species observed in both ion modes 
Figure 5.3.1. Percentage of the number of annotated lipids in negative ion mode together with the percentage of lipids 
significantly different across the three tissue types (q-value<0.05), healthy stroma from normal ovaries (HO), tumour tissue 
from serous ovarian carcinoma samples (Serous) and respective tumour associated stroma (Stroma). Relative abundance per 
tissue type per lipid class in negative ion mode. PE- phosphatidylethanolamine, PC- phosphatidylcholine, PS- 
phosphatidylserine, PA- phosphatidic acid, PG- phosphatidylglycerol, PI- phosphatidylinositol, SM- sphingomyelin, Cer- 
ceramide.  
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present a consistent change across the tumour samples and normal ovarian samples. In 
accordance with the negative ion mode data, ceramides and SM present an obvious decrease in 
the relative abundance on the tumour related tissues (tumour tissue and associated stroma) 
compared to the normal ovarian tissue.  
 
 
Figure 5.3.2. Percentage of the number of annotated lipids in positive ion mode together with the 
percentage of lipids significantly different across the three tissue types (q-value<0.05), healthy stroma 
from normal ovaries (HO), tumour tissue from serous ovarian carcinoma samples (Serous) and 
respective tumour associated stroma (Stroma). Relative abundance per tissue type per lipid class in 
negative ion mode. PC- phosphatidylcholine, PE- phosphatidylethanolamine, SM- sphingomyelin, Cer- 
ceramide, PS- phosphatidylserine, PG- phosphatidylglycerol, DG- diacylglycerol, TG- triacylglycerol. 
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As demonstrated by the number of significant annotated peaks and relative abundances 
across all tissue types, different phospholipids show different behaviour in cancer directly 
linked to their class, and consequently function. Interestingly, the majority of the molecular 
species from the PI, PG and PA classes appear to increase in tumour samples compared to 
control samples. Furthermore, a large proportion of these lipids increases gradually according 
to the severity of cancer in the tissue, being least abundant in normal ovarian tissue, increased 
in tumour-associated stroma and most abundant in tumour tissue. These three classes belong 
to the CDP-DAG pathway, where PA is converted to CDP-DAG by CDS, which in turn will 
be converted into PI by PIS1 (Phosphatidylinositol synthase) or into PG by PGS1 
(Phosphatidylglycerol synthase). The PA class can also be part of another pathway, called the 
Kennedy pathway, where other phospholipid classes, such as PE, PC and PS, are synthetized 
from PA and subsequently DAG (Figure 5.3.3).  
Interestingly, the PC class shows a similar trend to the ceramide and SM classes, 
decreasing in both tissue types belonging to the cancer patients. SM and ceramides are in fact 
mainly synthesised from PC, which suggests that the PC class is being produced at the same 
rate as it is being used for further lipid synthesis.  
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Looking at the two main phospholipid classes synthesised in this pathway, PE and PC, 
their behaviour does not follow the same trend as the PA class, suggesting that the Kennedy 
pathway is not as strongly affected as the CDP-DAG pathway in these cancer samples. 
Figure 5.3.3. Phospholipid synthesis pathways: Kennedy Pathway and CDP-DAG pathway, note: broken arrows indicate 
more than one step. DAGK- diacylglycerol kinase, PLD- phospholipase D, PLA2- phospholipase A2, LPCAT- 
lysophosphatidylcholine acyltransferase, ATX- autotaxin, LPAAT- lysophosphatidic acid acyltransferase, LPAGT- 
lysophosphatidylglycerol acyltransferase, LPEAT- lysophosphatidylethanolamione acyltransferase, PGP- phosphoglycolate 
phosphatase, PIS- Phosphatidylinositol synthase, PSS- phosphatidylserine synthase, PSD- phosphatidylserine 
decarboxylases, CPT- Carnitine palmitoyltransferase, EPT- diacylglycerol ethanolaminephosphotransferase, LPA- 
lysophosphatidic acid, PA- phosphatidic acid, LPE- lysophosphatidylethanolamione, PE- phosphatidylethanolamine, DAG- 
diacylglycerol, PC- phosphatidylcholine, LPC- lysophosphatidylcholine, SM- Sphingomyelin, CDP-DAG- cytidine 
diphosphate diacylglycerol, PGP- phosphatidylglycerol phosphate, PI- phosphatidylinositol, PG- phosphatidylglycerol, 
LPG- lysophosphatidylglycerol, PIPs- phosphatidylinositol phosphate 
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Table 5.3.1. Lipid species found by DESI-MSI in the ovarian cancer cohort in negative ion mode. Lipid species with absolute value of mean fold change 
equal or higher 1 for at least one of the conditions, and with sum intensities across the three tissue types equal or higher than 40 
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Table 5.3.1. Continuation 
  
 
141 
 
 
 
 
 
 
 
  
Table 5.3.2. Lipid species found by DESI-MSI in the ovarian cancer cohort in positive ion mode. Lipid species with absolute value of mean fold 
change equal or higher 1 for at least one of the conditions, and with sum intensities across the three tissue types equal or higher than 40 
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Table 5.3.2. Continuation 
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As emphasised before, phospholipids present different behaviour in cancer directly 
linked to their class, and consequently function. To better elucidate the changes in the different 
lipids annotated in this study, a table with the most significant lipids and with MFC values was 
created for both positive and negative ion mode (Tables 5.3.1 and 5.3.2). In these tables, the 
ions were included using the following criteria: MFC absolute value equal or higher than 1, 
sum of all relative intensities across the three tissue types with a value equal or higher 40 and 
q-value lower than 0.05. In the next section, the main changes in the phospholipid and 
sphingolipid classes are going to be further discussed and complemented with results from 
immunohistochemical analysis and targeted LC-MS.   
 
5.3.2. Signalling lipid metabolism  
 
5.3.2.1.Phosphatidic acid 
 
As stated previously, PA is a key intermediate in de novo membrane phospholipid 
biosynthesis, as well as in regulating cell proliferation, growth and survival [68]. Therefore, 
the role of PA in cancer has long been discussed, particularly as its function as a lipid second 
messenger molecule is well established [171]. As stated before, PA can be used to produce 
DAG (Kennedy pathway), or by the enzyme CDS to produce CDP-DAG. For that reason, the 
study of these two pathways for phospholipid synthesis in cancer metabolism is vital for a 
better characterisation of the PA class in cancer cells. Therefore, immunohistochemistry was 
performed on the two enzymes responsible for both arms of PA pathways, the PAP2, 
responsible for the synthesis of DAG from PA, and CDS1, responsible for the synthesis of 
CDP-DAG from PA (Figure 5.3.4). The results were analysed by a histopathologist, and the 
average of 22 carcinoma samples and 3 normal ovarian samples is shown in Figure 5.3.4.  
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When analysing the immunohistochemistry results for the two enzymes, it was clear 
that the expression of the enzyme PAP2 could not be observed in either of the tissue types, 
suggesting that this protein is not altered in these cancer samples. However, the enzyme CDS1 
was clearly expressed in the stroma and tumour tissue in the cancer samples but only weakly 
in the normal ovarian tissue (Figure 5.3.4), suggesting an alteration in the expression of this 
protein in cancer samples compared to healthy samples.  
PAP2, also known as LPP1, was first described by Kai et al in 1997 [187] in a mouse 
model, and was rapidly recognized as important in regulating cell signalling through 
lysophosphatidic acid (LPA) dephosphorylation, producing monoacylglycerol. Interestingly, a 
study where PAP2 was introduced into ovarian cancer cell lines demonstrated an increase in 
Figure 5.3.4. H&E staining together with immunohistochemistry results for the enzymes phosphatidic 
acid phosphatase 2 (PAP2) and phosphatidate cytidylyltransferase 1 (CDS1) in a serous ovarian 
carcinoma sample and normal ovarian sample. The tables represent the expression of these enzymes in 
the different tissue types analysed: N-normal ovarian tissue, T-tumour tissue, S-tumour associated 
stroma. DAG- diacylglycerol, PA- phosphatidic acid, CDP-DAG- cytidine diphosphate diacylglycerol  
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LPA hydrolysis and, consequently, a marked inhibition of cell proliferation and an increase of 
apoptosis [188]. With these findings it is clear that cancer cells would rather maintain the PAP2 
levels low, as high levels would block cell proliferation and survival. The results presented 
here are in agreement with the literature, suggesting that PA go towards the CDP-DAG 
pathway rather than the Kennedy pathway.  
Furthermore, the enzyme CDS1 is shown to be slightly increased in cancer samples. 
CDS1 has long been recognized as responsible for the phosphorylation and stabilization of p53, 
in response to any DNA damage at this checkpoint, being able to delay the cell cycle 
progression [189]. Nevertheless, TP53 (p53) is one of the most frequently altered genes in 
human cancers, with mutations being present in approximately 50% of all invasive tumours, 
leading to accumulation of CDS in cancer [190].  
For the PA class to respond to the increase of the CDP-DAG pathway observed on the 
immunohistochemistry results, and for the levels of these molecules to continue to be high, the 
synthesis of the PA class must also be one of the key changes in the lipid metabolism in cancer. 
The main pathways to generate PA are: phospholipase D (PLD), diacylglycerol kinase (DGK), 
and lysophosphatidic acid acyltransferase (LPAAT). As stated in the introduction, the 
expression of the enzyme PLD2 is described in the literature to be higher in a variety of cancer 
types [67, 69], leading to an overproduction of PA from PE and PC in cancer metabolism. To 
verify in our cohort that the increase in the PA class correlated with an increased expression of 
PLD2, immunohistochemistry of this enzyme was performed for the serous ovarian carcinoma 
samples, as well as normal ovarian samples as a control (Figure 5.3.5). 
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Figure 5.3.5. Immunohistochemistry results for the phospholipase D2 (PLD2) antibody in a serous 
ovarian carcinoma sample and a normal ovarian sample. The table represents the expression of this 
enzyme in the different tissue types analysed: N-normal ovarian tissue, T-tumour tissue, S-tumour 
associated stroma. PA- phosphatidic acid, PC- phosphatidylcholine, PE- phosphatidylethanolamine.  
 
When analysing the results, it is possible to corroborate what is stated in the literature, 
i.e. that the PLD2 expression is higher in both tumour-related tissue types (stroma and tumour) 
compared to the control samples, where the expression of this enzyme is not as intense (Figure 
5.3.5). The increase in PA levels is due to its active role in cell cycle progression [65, 66], via 
input from mTOR, as this protein activity is required for progression from G1 into S-phase 
[191]. The link between mTOR and PLD is a crucial pathway in cancer survival.  
For a long time, the de novo synthesis pathway through LPAAT was assumed to be 
used only in the synthesis of triglycerides in adipocytes. Nowadays, it is increasingly accepted 
that, as with PLD-produced PA, that PA produced by LPAAT-β also has a signalling function 
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[191]. In fact, when LPAAT protein expression is inhibited in certain cancers, such as in 
pancreatic adenocarcinoma cells, it reduces the cell proliferation and growth [192]. 
Considering this evidence of other sources of PA, it is clear that PA generated via the LPAAT 
and DGK pathways is also involved in the regulation of mTOR activity.  
Furthermore, in cancer cells, especially in K-Ras driven cancers, mTOR was 
demonstrated to respond to exogenous fatty acids, which are then used in de novo PA synthesis 
[68]. Some studies have investigated the impact of the fatty acid chain length on the activity of 
both mTOR1 and mTOR2. One group concluded that oleic acid (C18:1) caused a robust 
increase in mTOR1 and mTOR2 activity compared to other fatty acids (palmitic acid-C16:0, 
linoleic acid-C18:2 and arachidonic acid-C20:4) through an increase in the phosphorylation of 
ribosomal subunit S6 kinase (S6K) at Thr-389 (mTOR1) and Akt at Ser-473 (mTOR2) [191]. 
Palmitic acid was the fatty acid with the least impact on mTOR activity. From free fatty acids 
to complex PA, mTOR was also responsive to PA (16:0/18:1) but not so much to PA 
(16:0/16:0) [193]. In fact, the latter was shown to promote the disassembly of mTOR2 and 
inhibit the phosphorylation of Akt by mTOR2 [194]. This evidence strongly suggests that fatty 
acid residue composition is important for the PA-mTOR interaction.  
In this study, although the relative abundance of PA class was small, a substantial 
number of species were significantly changed in cancer compared to control tissue, with a q-
value lower than 0.05 They all showed a positive and high MFC, as listed in Table 5.3.1, 
illustrating the essential role of PA in cancer metabolism. Furthermore, the significant m/z 
values highlighted in Table 5.3.1 were assigned to PAs with fatty acids composed of 18 or 
more carbon atoms. Specifically, the smallest significant m/z value corresponds to PA (36:1) – 
most probably PA (18:1/18:0). These findings are in agreement with the previous studies 
described above and further emphasize the impact that the incorporation of specific chain 
length fatty acids can have on phospholipid synthesis and, consequently, on cancer cell 
metabolism.  
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Figure 5.3.6. Akt/PI3K/mTOR pathway and the impact of mTOR signalling pathway in protein and 
lipid synthesis, glycolytic metabolism, mitochondrial metabolism and cell survival with the respective 
proteins. Adapted from [93] 
 
 
5.3.2.2.Phosphatidylinositol 
 
The PI class is a precursor of PIPs, a group of secondary messengers in the signalling 
pathways which have direct roles in the PI3K/Akt/mTOR pathway. PIPs have direct roles in 
activating proliferation, maintaining survival and promoting migration [61, 62]. More 
specifically in this pathway, PI3K catalyses the production of PI(3,4,5)P3 from PI(4,5)P2, 
which binds to the enzyme Akt, inducing its travel to the membrane and inducing 
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conformational changes in preparation for phosphorylation by pyruvate dehydrogenase kinase 
(PDK)1, the crucial step in Akt1 activation. Activated Akt can directly and indirectly activate 
mTOR1 by phosphorylation [195].  
This pathway is affected in cancer metabolism at different levels. Increased mTOR 
activity in human cancer can be caused by enhanced membrane phospholipid recruitment and 
elevated Akt1 kinase activity [1]. Another well documented alteration in this pathway is the 
change in PI3K, quoted as a leading cause of malignancy [64]. Loss-of-function mutations in 
PI3K inhibitors, such as PTEN have been widely studied as a cause of high PI3K expression 
in cancer [93].  
PIPs are also important mediators in the regulation of PLD activity and subcellular 
localization, as PLDs have a PI(4,5)P2 binding region. Interestingly, phosphatidylinositol 4-
phosphate 5-kinase (PI4P5K), the enzyme that generates PI(4,5)P2, is activated by PLD-
produced PA [196].  
 
With all these changes linked to the PI class, PI species are expected to show changes 
in a cancer environment linked to the changes in the pathway. Interestingly, the PI class mostly 
showed a positive MFC for the significant ions selected from DESI-MS. The three PI species 
with highest MFC in Table 5.3.1 all have between 38 carbons and 40 carbon atoms in their 
fatty acid residues, with two of them having 6 double bonds. This increase in cancer suggests 
that cells respond to the need of PIP signalling cascades, and therefore their precursors as well 
[93]. These results are in agreement with another study in the literature where it was shown 
that arachidonic acid - C20:4 and docosahexaenoic acid - C22:6 have a higher impact on the 
Akt pathway trough PI synthesis, and consequently PIPs, compared to linoleic acid - C18:2 
and eicosapentaenoic acid - C20:5 [197].  
To refine the results in DESI, the results were compared to LC-MS results of the method 
developed in the chapter three. For this analysis the five most intense PIs were targeted and 
intensities were normalised to the internal standard PI (18:1-d31-16:0) (Figure 5.3.7).  
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The relative intensity of the different species compared to the internal standard are 
plotted in Figure 5.3.7. The PI species which were the most significant species in the LC-MS 
data as well as the most significant values for DESI-MS data, were PI (38:3) and (40:6). They 
both show a gradual increase in relative intensities, from normal ovarian tissue, through 
tumour-associated stroma to tumour tissue.  
Another interesting observation in the LC-MS data is that for the mixed tumour group, 
the wide range of values observed corresponds to the range found across the stroma and tumour 
tissue groups together. These results in the mixed tumour group emphasise the heterogeneity 
of tumour samples and the importance of the spatial distribution of the ions obtained with 
DESI-MS; the tissue analysis was acquired at a spatial resolution of 100 µm, allowing 
differentiation of tissue types, which with LC-MS is difficult to achieve.  
 
5.3.2.3.Sphingolipids  
 
Figure 5.3.7. LC-MS results from the semi - quantitative method for five different phosphatidylinositol species (PI) 
across four different groups of samples: OV- healthy stroma from normal ovaries, T- serous ovarian carcinoma samples 
where the H&E analysis revealed between 90% and 100% of tumour cells, S- serous ovarian carcinoma samples with a 
tumour group where the H&E analysis revealed between 90% and 100% of stromal tissue, mixedT- serous ovarian 
carcinoma samples where the samples had mixed stroma tissue and tumour tissue. Relative abundances normalized 
using the internal standard PI (18:1-d31-16:0).  
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As discussed in the introduction, sphingolipids are also involved in pro-apoptotic and 
anti-proliferative activities. In this study, both SM and ceramide classes showed negative 
values for the MFC in both stroma and tumour compared to normal ovary, suggesting that the 
relative abundance of these classes decreased in cancer. In fact, ceramides and SM are 
precursors of two sphingolipid species (S1P and C1P) with key roles in proliferation and 
survival of cancer cells [56-58, 198]. 
In positive ion mode, SM (d42:2) (detected as [M+H]+ and [M+Na]+) and SM (42:3) 
presented the highest significance in their decrease in tumour tissues compared to normal 
ovarian tissues. In positive ion mode, SM ionize more easily than in negative ion mode due to 
their choline head group. For this reason, in negative ion mode, it was possible only to detect 
SM (42:2) and (34:1). On the other hand, ceramides were detected in negative ion mode, with 
discriminatory species being Cer (42:2), Cer (40:2) and Cer (40:1). The ceramide with the most 
significant q-value in positive ion mode was Cer (42:2). In the literature, sphingolipids found 
usually saturated and monounsaturated VLCFA residues [199], perfectly in agreement with our 
results described above.  
 
Figure 5.3.8. LC-MS results from the semi - quantitative method for four different ceramide (Cer) species across four 
different groups of samples: OV- healthy stroma from normal ovaries, T- serous ovarian carcinoma samples where the 
H&E analysis revealed between 90% and 100% of tumour cells, S- serous ovarian carcinoma samples with a tumour group 
where the H&E analysis revealed between 90% and 100% of stromal tissue, mixedT- serous ovarian carcinoma samples 
where the samples had mixed stroma tissue and tumour tissue. Relative abundances normalized using the internal standard 
Cer (d18:1/17:0). 
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The LC-MS data does not show any significant changes apart from Cer (d18:1/16:0) 
(Figure 5.3.8), probably due to the heterogeneity of the tissue. The sphingolipids present the 
same pattern as the PI class, where the mixed tumour covers the range of both stroma and 
tumour tissues. Interestingly a study performed in HeLa cells, demonstrated that an increase in 
apoptosis was linked to a shift in the sphingolipid composition from fatty acids with 24 carbons 
to smaller fatty acids with 16 carbons [200]. They concluded that C24 (and C26) sphingolipids 
may have multiple functions whose dysregulation could lead to pathological consequences. In 
fact, in our LC-MS data, Cer (d18:1/16:0) is substantially higher in the normal ovary compared 
to tumour related tissues, where it is expected to have a deregulation linked to a decrease in the 
apoptotic functions.  
In the literature, sphingolipid-related enzymes such as S1PP and SPL have been 
described to have a higher expression in many cancer conditions. These enzymes, with critical 
roles in cancer progression, lead to enhanced S1P production in cancer cells [201]. Both 
ceramides and more directly SM are directly linked to the synthesis of S1P, leading to a high 
consumption of these substrates in cancer metabolism, directly reflected in our results.  
Sphingolipids are also involved in membrane stability and fluidity through the 
membrane domains, the lipid rafts. These domains do not only play unique structural roles but 
also act as assembly points for signalling molecules and membrane trafficking of specific 
proteins [202]. In addition to the SM class, these membrane domains can also incorporate 
ceramides for functions linked to apoptosis. These domains rich in ceramides allow to amplify 
a weak primary signal, for example death receptors that transmit a strong signal to the cell and 
thus trigger apoptosis. When ceramides are replaced with cholesterol, these domains have a 
completely different functionality, becoming involved in normal cell signalling. Due to its 
function, cholesterol has long been reported to accumulate in malignant tissues and more recent 
evidence has shown that the cholesterol content in tumour cells is higher than in normal cells 
[1]. Equally, cancer cells have been suggested to display higher levels of cholesterol-rich lipid 
rafts compared to non-cancer cells [202, 203].  
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5.3.3. Structural lipid metabolism  
 
5.3.3.1.Phosphatidylcholine  
 
The PC class is the most abundant structural phospholipid class found in our cell 
membranes. The relative intensity of all PCs together shows a slight decrease in tumour tissue 
compared to normal ovary. Despite having a substantial standard deviation, the stroma tissue 
appears to be the lowest of the three tissue types in relative intensity. The choline metabolism 
is known to be altered in cancer, which can have a vital impact on the synthesis of PC species 
[204, 205]. The important question is, do these changes have an impact on the fatty acid 
composition of these lipid species?  
PCs, due to their choline head group, ionise readily in positive ion mode. Interestingly, 
the diacyl species containing fatty acids with 38 or more carbons as well as polyunsaturated 
fatty acids are increased in cancer. On the other hand, PC with short and monosaturated / 
saturated fatty acids are more strongly expressed in the control normal ovarian samples. A 
previous study identified monosaturated and saturated fatty acid PCs as an inhibitor of 
metastatic activity in epithelial tumour cell [206], which is corroborated by these findings.  
Looking at the specific molecular species across the data from the two methods (DESI-
MS and LC-MS), PC (38:6), identified as PC (16:0/22:6) in the LC-MS data, gradually 
increases in cancer from the normal ovary through tumour associated stroma (Figure 5.3.9). 
Another interesting observation carbons in both LC-MS and DESI-MS analysis is that 
diacylPC species with a chain length of 40 carbons are highly expressed in tumour tissue 
compared to both stroma and normal ovary, suggesting they are characteristic of the tumour 
itself and not the whole environment of a tumour sample. The membrane fatty acid composition 
has been described to be altered in cancer to adapt and facilitate the fluidity of the membrane 
and signalling transduction [77].  
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Figure 5.3.9. LC-MS results from the semi - quantitative method for seven different lysophosphatidylcholine (LPC) species and thirteen 
phosphatidylcholine (PC) species across four different groups of samples: OV- healthy stroma from normal ovaries, T- serous ovarian carcinoma 
samples where the H&E analysis revealed between 90% and 100% of tumour cells, S- serous ovarian carcinoma samples with a tumour group where the 
H&E analysis revealed between 90% and 100% of stromal tissue, mixedT- serous ovarian carcinoma samples where the samples had mixed stroma 
tissue and tumour tissue. Relative abundances normalized using the internal standard PC (15:0/15:0) for the PC class and LPC ( 17:0) for the LPC class. 
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Looking to the different relative intensities the different groups, between the tumour, 
stroma and mixed tissue in the LC-MS samples, it is possible to understand how heterogeneous 
the tumour tissue can be. Characterising this heterogeneity provides valuable information for 
studying the lipid metabolism in this disease, which can easily be achieved by DESI-MS.   
LPC synthesis and hydrolysis is accelerated in cancer to respond to the cell need in 
cancer metabolism [206]. As the analysis by DESI-MS was performed only for peaks between 
600 and 1000 m/z, it was not possible to examine the differences in the LPC class. However, 
with the LC-MS data, and due to the importance of LPC in cancer metabolism, it was possible 
to analyse the LPC species with highest intensities (Figure 5.3.9).  
LPCs can be used to synthesise PC species, raising the question whether these two 
classes show the same trends. Saturated LPC species do not present any significant change 
across the different tissue types. However, all unsaturated species are increased in cancer, 
mostly compared with both stroma and normal ovary. LPC (20:4) is increased in both tumour 
and stroma, suggesting a different role and composition in cancer metabolism compared to the 
other LPC species. Different studies have identified lysophospholipids, specifically LPC 
species, as potential biomarkers in ovarian cancer [81, 92].  
 
5.3.3.2.Phosphatidylethanolamine  
 
PE is a structural phospholipid, not just in cell membranes but also crucially in the 
mitochondria for the synthesis of other phospholipids, such as PS [207]. Overall, this 
phospholipid class did not show significant changes when comparing the three different tissue 
types.  
Comparing the data in both positive and negative ion modes, positive ion mode 
identified more alkyl-acyl species, while in negative ion mode, more diacyl species were 
detected.  
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Analysing the data acquired in negative ion mode, besides the alkyl-acyl PE species, 
the longer diacyl PE species with a higher degree of unsaturation possess the highest MFC 
values. For example, the two top values correspond to PE (40:3) and PE (38:6), with VLCFA 
Figure 5.3.10. LC-MS results from the semi - quantitative method for thirteen phosphatidylethanolamine (PE) species 
across four different groups of samples: OV- healthy stroma from normal ovaries, T- serous ovarian carcinoma samples 
where the H&E analysis revealed between 90% and 100% of tumour cells, S- serous ovarian carcinoma samples with a 
tumour group where the H&E analysis revealed between 90% and 100% of stromal tissue, mixedT- serous ovarian 
carcinoma samples where the samples had mixed stroma tissue and tumour tissue. Relative abundances normalized using the 
internal standard PE (15:0/15:0). 
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and 3 to 6 double bonds. Interestingly, this is a similar trend observed for the PC class described 
above.  
One very good example of the value of the LC-MS data in refining the profiling data 
acquired by DESI-MS are the results for PE (18:0/20:4) (Figure 5.3.10). DESI-MS cannot 
distinguish the species PE (O-38:6) / PE (P-38:5) / PE (38:4) as they have close m/z values. 
With LC-MS, targeting the lipid PE (18:0/20:4) specifically, we can infer that the m/z 748.53 
corresponds to PE (38:4), as they both show the same trend, a significant decrease in both 
tumour related tissues compared to the control normal ovary. Interestingly, besides PE (38:4), 
most of the other diacyl PE species increase in cancer compared to the normal tissue. In the 
LC-MS data, while the lower m/z PEs did not show any substantial change, the higher m/z PEs 
with very long chain fatty acids (VLCFA) continued to show an increase in cancer. These 
results, together with the overexpression of PLD, and the increase of the PA class in cancer, 
suggest that there is a selectivity in the fatty acid composition for the PE used by PLD to 
synthetize PA. In the LC-MS data (Figure 5.3.10) it is possible to observe once more the 
importance of specially localize the lipid species detected across the different tissue types, the 
advantage of DESI-MSI. 
Levels of circulating phospholipids such as LPC and plasmenyl-phosphoethanolamine 
(PE plasmalogen) were found to be depleted in ovarian cancer patients [83]. Studies in other 
types of cancer also showed alterations in the PE composition, such as in breast cancer [70], 
where changes in the fatty acid composition were also analysed.  
 
5.3.3.3.Phosphatidylserine  
 
From a general perspective, the relative abundance of the entire PS class does not 
change markedly across the three tissue types. However, when analysing the different PS 
species on both platforms, LC-MS and DESI-MS, it is possible to conclude that there are 
changes across the different PS species with different fatty acid composition. A remarkable 
change observed with both methods is PS (34:1) and PS (36:1), which are increased in normal 
ovary compared to both stroma and tumour tissue. At the same time, the PS species with 5 or 
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more double bonds are increased in tumour gradually compared to stroma and normal ovary. 
These changes confirm the trend towards higher double bond number PL in cancer patients 
compared to the healthy patients. 
 
 
The PS class has a very similar trend compared to the PE and PC classes in this study. 
However, the changes in the VLCFA are not exactly the same, as a PS with 40 carbons and no 
change in cancer compared to the normal ovary was also observed. This could be due not just 
to its different distribution across the cell membrane and organelles but also connected to its 
crucial apoptotic role in cell life. When PS are transferred from the inner to the outer leaflet of 
the membrane, apoptotic signals are realised, preparing cells for programmed cell death [207].    
Figure 5.3.11. LC-MS results from the semi - quantitative method for eight different phosphatidylserine (PS) species 
across four different groups of samples: OV- healthy stroma from normal ovaries, T- serous ovarian carcinoma samples 
where the H&E analysis revealed between 90% and 100% of tumour cells, S- serous ovarian carcinoma samples with a 
tumour group where the H&E analysis revealed between 90% and 100% of stromal tissue, mixedT- serous ovarian 
carcinoma samples where the samples had mixed stroma tissue and tumour tissue. Relative abundances normalized 
using the internal standard PS (17:0/17:0). 
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5.3.4. Fatty acid metabolism  
 
In negative ion mode, the range between 150 and 500 m/z was also analysed to 
investigate the changes in the free fatty acid composition, as they are the basic building block 
of the main lipids. The m/z values in this range were matched with the different fatty acid 
masses in the form of [M-H]-, covering the most abundant chain lengths and saturations. The 
MFC of the ratios of their normalized relative abundances between different tissue classes were 
calculated (Figure 5.3.12).  
 
 
Figure 5.3.12. Mean fold change for the relative abundances of the m/z values matched with the main 
fatty acids. Comparison between tumour tissue from high grade serous carcinoma samples (Cancer) 
and healthy stroma from normal ovarian samples (Normal), Cancer vs cancer associated stroma form 
high grade serous carcinoma samples (Cancer associated stroma) as well as Cancer associated stroma 
and Normal. De novo fatty acid synthesis pathway and omega-3/ omega-6 pathways.   
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As performed before for the phospholipid range, the three different ratios analysed for 
the fatty acids were: cancer tissue vs normal stroma tissue, cancer tissue vs cancer-associated 
stroma and the cancer-associated stroma vs normal ovarian tissue. The MFC values for the 
fatty acids in the cancer vs normal and cancer vs cancer-associated stroma plots present a very 
similar pattern. These changes reflect an increase of the level of unsaturation and chain length 
in cancer compared to both stroma associated and normal ovarian stroma, the latter being more 
prominent. Interestingly, the MFC values for unsaturated fatty acids with 26 carbons were the 
highest in these two comparisons. Although it was possible to see a similar trend regarding the 
increase of LCFA, the number of double bonds did not follow the same pattern when analysing 
the MFC between the stroma and normal tissue. The unsaturated fatty acids decreased in the 
stroma compared to the normal ovarian tissue.  
As we are comparing ratios, the results suggest one of the two options: an actual 
increase in the long chain fatty acids or a decrease in the short chain fatty acids. To better 
understand the fatty acid metabolism in cancer, immunohistochemistry analysis was performed 
for the main enzymes in the fatty acid pathways. The first enzyme to emphasise is FASN, 
which is the main enzyme responsible for the synthesis of palmitic acid, the starting block for 
almost all fatty acids.  
As stated in the introduction, an increase in FASN is one of the hallmarks of cancer, 
which is well described in the literature [74, 75]. It is responsible for the increase of de novo 
FA synthesis [72, 73]. This enzyme is responsible for converting acetyl-CoA and malonyl-CoA 
into palmitic acid. Therefore, the samples were tested for the expression of FASN by 
immunohistochemistry. The results showed a substantial increase of expression in the tumour 
samples compared to the normal ovarian samples, more prominent in areas of the tissue 
dominated by tumour cells (Figure 5.3.13). The enzyme responsible for the synthesis of acetyl-
CoA is ATP citrate lyase (ACLY) which is less well studied but also described as increased in 
different cancer types [77]. In the analysis it was possible to observe that the expression of this 
enzyme showed a similar pattern in all samples.  
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Figure 5.3.13. H&E staining together with immunohistochemistry results for the main enzymes in the de novo fatty acid synthesis and fatty acid 
uptake. in a Serous ovarian carcinoma sample and normal ovarian sample. CD36-cluster of differentiation 36, FASN- fatty acid synthase, ACLY- 
ATP citrate lyase, ACC- coenzyme A carboxylase, CES1- carboxylesterase 1, NFKB- nuclear factor kappa B, SCD1- stearoyl-coenzyme A 
desaturase, ELOVL1- fatty acid elongase 1. The tables represent the expression of these enzymes in the different tissue types analysed: N-normal 
ovarian tissue, T-tumour tissue, S-tumour associated stroma.  
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In the de novo fatty acid synthesis pathway, the synthesis of palmitic acid requires not 
only acetyl-CoA but also malonyl-CoA, which is synthetized by ACACA. The expression of 
this enzyme was neither detectable in the normal samples nor in the tumour associated-stroma 
from the tumour samples. However, in the cancerous tissue the expression of this enzyme was 
high, supporting the hypothesis of an increase in the de novo fatty acid synthesis pathway. After 
the synthesis of palmitic acid, fatty acids can follow different paths, as energy sources through 
β-oxidation, as building blocks for more complex lipids or undergoing desaturation and 
elongation to respond to the different needs of the cell life.  
In fact, elongation of fatty acids is gaining recognition as an important aspect of cancer 
biology. The increase of de novo synthesis also implies overexpression of elongation and 
desaturation processes in de novo lipogenesis. The overexpression of ELOVL1 (as described 
in the human protein atlas [208]) is strong evidence of further fatty acid synthesis for cancer 
metabolism and consistent with the results presented here. In this study, the expression of 
ELOVL1, responsible for fatty acid elongation, and SCD1, responsible for the desaturation of 
palmitic acid, were also evaluated. The results were consistent with the literature, in that they 
were overexpressed not just in tumour tissue but also tumour associated-stroma compared to 
normal tissue [77].   
A further important aspect is external fatty acid uptake, as cells under normoxic 
conditions, do not have the capacity to synthetize all fatty acids. Furthermore, medium and 
long chain fatty acids are commonly used for β-oxidation as discussed above, and consequently 
for the production of energy [209]. Compared to the de novo fatty acid synthesis, the impact of 
fatty acids in the energy production through β-oxidation in cancer metabolism is poorly 
understood.  
Related to the uptake of fatty acids, three different enzymes were also analysed by 
immunohistochemistry: the fatty acid transporter CD36 and two enzymes related to the 
hydrolysis of long chain fatty acids, CES1 and NFKB. CD36 is a transmembrane protein with 
various functions in fatty acid uptake. NFKB induces the enzyme CES1, which catalyses the 
lipolysis of triacylglycerols (also termed triacylglycerol hydrolase (TGH)) [210]. In these IHC 
results, the expression results for most of these enzymes were negative and limited information 
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was available to be able to draw further conclusions about these enzymes. The literature 
suggests that different types of cancer likely differ in their clinical response to the increase of 
β-oxidation, depending upon their energy requirements [209, 211].  
Although not as well described in cancer metabolism as the de novo fatty acid synthesis, 
β-oxidation, also known as fatty acid oxidation, plays important roles as an energy source, ideal 
for a variety of cancer types to increase their energy production. Different studies have 
demonstrated that cancer cells require β-oxidation, particularly under stress conditions [209]. 
The process starts with the transport of FA-CoA from the cytosol across the outer 
mitochondrial membrane after they have been converted to acyl-carnitines. Within the 
mitochondria, FAs are then repeatedly cleaved to produce acetyl-CoAs that feed into the Krebs 
cycle [211].  
Ovarian cancer is described in the literature as one of the cancers that take advantage 
of the adipose tissue in the neighbourhood and its reservoir of TGs as a source of fatty acids in 
the cancer energetic metabolism [212]. Evidence for this can be found in the fatty acid binding 
protein 4 (FABP4), a lipid chaperone, which is implicated in providing fatty acids from 
surrounding adipocytes for ovarian tumours [212]. Another interesting study reveals the 
importance of the enzyme monoacylglycerol lipase (MAGL) in the hydrolysis of the final fatty 
acids from MG. By knocking down the enzyme MAGL, it was possible to lower the free fatty 
acid levels and reduced pathogenicity of melanoma and ovarian cancer cells in vitro and in 
vivo, while overexpression showed the opposite phenotype [213].  
Overall, the different lipid species have specific roles in the cell cycle, and consequently 
in cancer metabolism. There is a huge gap in what is known about cancer metabolism and 
lipids. However, it is obvious that not just the lipid class, but also the fatty acid composition of 
the different phospholipids and sphingolipids can have an impact on the cancer cell biology. 
Furthermore, not all the phospholipids that incorporate the same fatty acids have the same 
impact in cancer metabolism due to their very specific roles in the cell.  
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6. Summary / Conclusion / Future Work  
 
Histopathology is currently the gold standard technique used for routine cancer 
diagnosis, supplemented with immunohistochemical tests. Histopathological analysis relies on 
the interpretation of each histopathologist, which can lead to some uncertainty. Using a 
machine to determine the molecular composition of the tissue, which could then be used to 
identify and diagnose any potential pathology, would make a decision more reliable, faster and 
user independent. One of the major problems of cancer is the fact that it is not a single disease 
but a collection of different diseases with different outcomes, making cancer very patient 
dependent. With the molecular information, the metabolism can be studied and evaluated, not 
just relying in a single molecule but a group of molecules, and consequently a more complete 
map of the pathways and metabolism. The possibility to probe in depth into the molecular 
composition, can enable a more personalized treatment and consequently tremendously aid the 
cancer diagnosis journey.  
Ovarian cancer is one of the deadliest cancers in women and therefore requires better 
diagnostic tools. There are many different challenges in ovarian cancer, starting with the origin 
of the tumour. It is well known that most ovarian carcinomas have epithelial characteristics, 
but there are various theories about where these cells originate from. With the ambiguous origin 
and diverse number of ovarian tumours, ovarian cancer diagnosis could improve when 
complemented with information about the molecular composition of tumour tissues.  
Based on the spatial distribution of the molecular profile, DESI-MSI has been shown 
to be a potent technique for the characterisation of different tissue types and cancer types in the 
last decade. DESI-MSI has been applied for tissue characterisation of brain, breast, colorectal 
and liver cancers, among others, and consequently has been proposed as a diagnosis tool to 
complement histology. However, ovarian cancer was not part of the portfolio previously 
analysed and characterised by DESI-MSI.  
The molecular composition of a DESI-MS spectrum is rich in phospholipids and 
sphingolipids, complex molecules with vital functions in the cell metabolism. There are a few 
hallmarks of cancer described in the literature directly linked to lipid metabolism, such as the 
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increase of de novo fatty acids and membrane phospholipid fluidity. Therefore, lipid 
composition has gained interest due to the changes it indicates in cancer metabolism.  
This study aimed to evaluate DESI-MSI as a diagnostic tool for ovarian cancer, as well 
as using the same data to explore the lipid changes in cancer.  
To add ovarian cancer to the cohort of cancers previously analysed by DESI-MS, a total 
of 110 EOC and control samples were analysed, and the different tissue types found were 
characterised. The samples were grouped according to the type of EOC (endometrioid 
carcinoma, clear cell carcinoma and serous carcinoma) and the degree of aggressiveness 
(borderline and malignant tumours). Chapter three describes the results obtained using the 
DESI-MS spectrum to identify the different groups analysed, as well as the different tissue 
types found in the same group of samples. This chapter resulted in a paper, the first to use 
DESI-MSI in ovarian carcinoma samples [165].  
The results demonstrated that serous ovarian carcinoma can be well distinguished from 
the other two types of EOC analysed, as well as from both control groups, normal ovary and 
epithelial cells from fallopian tube. However, clear cell carcinoma and endometrioid carcinoma 
are difficult to separate from each other, possibly because both carcinomas arise from 
endometriosis [21], a common feature which can lead to a similar metabolism and 
consequently, a comparable lipid profile. Another obstacle to the separation of these two groups 
of carcinomas is the low percentage of incidence, reflected in the low number of samples 
obtained, compared to serous ovarian carcinoma which is much more frequent in the 
population. Borderline tumours, also with a poor abundance in this study, already demonstrated 
significant differences from both malignant tumours and normal ovaries. This is a huge 
advantage for diagnostic purposes as borderline tumours are considered a challenge for the 
histopathology community [170].  
Despite the low number of samples in some of the groups, the lipid patterns observed 
showed how unique the lipid metabolism is in this variety of tumours. Thus, there is a huge 
potential for tumour characterisation and identification.  
The analysis performed on each individual sample proved the ability of DESI-MSI to 
identify the different tissue types in ovarian cancer down to a microscopic level, allowing the 
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establishment of a very accurate correlation between the morphology and biochemistry of a 
tissue type. The different tissue types found in individual samples, both normal and tumour 
samples, presented a specific lipid pattern, with tissue classification accuracy values always 
higher than 90%. The boundaries of each tissue type observed in the optical image were 
remarkably matched with the different RMMC components, the prediction of all pixels based 
on specific annotated pixels representing each group / tissue. The heterogeneity of the tumour 
tissue well described in the literature can be observed clearly with the different lipid spatial 
distributions. However, the tissue characterisation is so unique that it allows us to observe these 
well-defined boundaries of each tissue type.  
The two main tissue types found in serous ovarian carcinoma samples were the tumour 
tissue and the tumour associated stroma tissue, which were easily distinguishable when 
analysing each sample separately. The significant number of serous ovarian carcinoma samples 
allowed us to see if the differentiation between stroma and tumour tissues in cancer patients 
was maintained when analysing multiple samples together. Despite the heterogeneity between 
patients and samples, this differentiation was still very positive for the entire serous ovarian 
carcinoma cohort, demonstrating the differences in the lipid metabolism across the different 
tissue types. More interestingly, with the RMMC model created for this cohort, together with 
both the normal ovarian stroma and epithelial tissue from fallopian tube, it was possible to 
observe a separation in the tissue types linked to their ontogeny. Epithelial normal tissue was 
closer to tumour tissue then to tumour associated stroma, and normal ovarian stroma was closer 
to the tumour associated stroma then to tumour tissue. These results reinforce the ability of 
DESI-MSI to perceive the characteristic and unique lipid profile of each tissue type.  
The prediction of a new and unseen sample would be the key application of this 
technique, offering comprehensive histological diagnosis more quickly and objectively than 
could be provided by a histopathologist. A model acquired for the serous ovarian carcinoma 
was tested for the prediction of a completely blind and independent sample, with unknown 
distribution of the tumour associated stroma and tumour tissue. The accuracy of the tissue 
characterisation, validated by a histopathologist, as well as the definition of clear boundaries 
of the tumour, demonstrated the potential of DESI-MSI as a diagnostic tool.  
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Profiling MS instruments together with a DESI stage proved to be a valuable tool for 
tissue characterisation and consequently a possible device for cancer diagnostics [139-141, 
143]. However, targeted MS instruments, such as a triple quadrupole instrument, would make 
the process faster, cheaper and simpler to use. The capability of these instruments coupled with 
a DESI stage for tissue characterisation with the use of a small number of lipid species was 
also tested with very promising results. Furthermore, the use of a very small number of lipids 
for tissue differentiation demonstrates how different the cellular lipid content is in cancer 
metabolism. The positive outcome of these experiments increases the likelihood that this 
technique can be used as a clinical diagnostic tool. The next stage would be improving the 
bioinformatics tools we have for imaging data sets to be able to process targeted data as we 
have for profiling data sets.  
Lipid content in the serous ovarian carcinoma cohort was also analysed to better 
understand the lipid changes in the cancer metabolism. Although there is already some 
knowledge about lipid changes as hallmarks of cancer metabolism, the big picture of the lipid 
metabolism in cancer is far from being completely understood.  
To support the lipid changes found in the DESI-MS data, a semi-targeted LC-MS 
method was developed in order to refine and analyse in depth the relative abundances of these 
lipid species. The method was successfully developed for the analysis of PC, LPC, PE, PI, PS 
and Ceramide classes, which includes lipids with different functions and locations in the cell.  
Interestingly, the PA class was well detected in the DESI-MSI data, and one of the 
classes with the most significant changes in cancer samples across the entire class. PA, as the 
mother of all phospholipids, is normally present in very low abundance. Although this 
phospholipid class can be difficult to detect in profiling analysis, the relative intensity of the 
different PA species was always higher in carcinoma samples compared to normal ovarian 
samples. These changes can be directly linked to its core position in the phospholipid synthesis 
as well as to its function in the activation of the mTOR/Akt/PI3K signalling pathway. The 
mTOR/Akt/PI3K is a crucial signalling pathway, directly involved in cell cycle progression 
and survival, which is deregulated in most of the cancer types. The PA class has a direct role 
 
169 
 
in stimulating mTOR expression by competing with the action of rapamycin, making the PA 
class crucial for lipid metabolism in cancer.  
Linked to this pathway, the PI class also demonstrated slight differences in relative 
abundance. In both LC-MS and DESI-MSI methods, PI species were increased in tumour and 
tumour associated stroma compared to normal ovarian tissue, showing a similar trend to the 
PA class. In contrast, sphingolipids were consistently decreased in carcinoma samples 
compared to normal ovarian samples. These changes can be linked to their roles and position 
in the membrane domains lipid rafts. These domains are the key to some signalling transduction 
processes as well as the transport of certain molecules, making sphingolipids essential in the 
metastatic process.  
PA is involved in two pathways for the synthesis of other phospholipids that appear to 
have different behaviours in cancer cells. For example, PI is synthesized from PA in the CDP-
DAG pathway, and they both present similar changes across the different tissue types. 
However, other phospholipid classes, such as PC and PE, did not present the same changes 
across the entire class, but were also linked to their fatty acid composition. These two lipid 
classes can be synthesized by the PA class through the Kennedy pathway. To better 
comprehend the changes in the phospholipid pathway the expression of different enzymes 
specific of each pathway (PAP2 in the Kennedy pathway and CDS in the CDP-DAG pathway) 
were analysed. Interestingly, these enzymes revealed that the expression of CDS is higher in 
cancer patients but PAP2 could not be detected. These results strongly suggest once more that 
PA is being used in the CDP-DAG pathway at a higher rate than in to Kennedy pathway. In 
fact, the increase of the PA class also suggested a high synthesis of this class in cancer. The 
PLD enzyme synthesizes PA through PC and PE species, which were also overexpressed in 
cancer samples.  
The changes observed in the LC-MS data were mostly consistent with DESI-MSI. 
However, all the results obtained in the LC-MS analysis showed that cancer samples with a 
lower percentage of stroma have a completely distinct profile from the cancer samples with a 
higher percentage of stroma. This information is lost when samples are categorized in tissue 
banks or other tissue sources, as it is difficult to predict the percentage of stroma each given 
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tissue can have by histological assessment. With DESI, the spatial information is not lost, and 
we can even detect the heterogeneity across the same tissue type by the different lipid 
distribution.  
 
The analysis of the lipid composition in ovarian cancer samples demonstrated that 
changes can occur depending on the lipid class and also depending on the fatty acid 
composition. Fatty acid composition is proven to be important in cancer metabolism [75]. In 
fact, de novo fatty acids synthesis was one of the first lipid hallmarks described in the literature 
[6]. The need of the cancer cell to expand and build new membranes, as well as the need for 
extra energy leads them to increase the production of fatty acids.  
Ovarian cancer is known to use the adipose tissue surrounding it as a source of fatty 
acids, causing an increase of fatty acid uptake in addition to the usual de novo fatty acid 
synthesis [1, 212]. The different analysis performed, in the free fatty acid results and the 
phospholipid composition, showed a consistent increase of VLCFA and unsaturations in cancer 
samples compared to normal samples.  
Immunohistochemistry results also demonstrated an overexpression of the enzymes 
responsible for the de novo synthesis, as ACLY, ACACA an FASN. The two enzymes linked 
to the elongation and saturation processes SCD1 and ELOVL1 in the fatty acid pathway, were 
also analysed and shown to be increased in tumour tissue as well as in the surrounding stroma. 
These results are in agreement with the increase of longer and more unsaturated fatty acids, 
both in the free pool and incorporated in the phospholipids. The impact that the fatty acid 
composition has on the membrane fluidity can also explain these changes, as more 
unsaturations leads to greater membrane fluidity, which is a key feature for proliferation and 
signalling transduction [1, 211].  
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The low number of certain ovarian carcinoma groups was an obstacle to better analysis 
of the alterations between the different tumour types and malignancies. As such, performing 
another study with a more even number of samples across the different ovarian carcinomas 
would add value to the findings of this study, as well as possibly revealing more about the lipid 
metabolism in the endometriosis driven carcinomas. With the increased number of samples, it 
would also be possible to have a base model to extend the blind sample prediction to other 
samples besides the serous ovarian carcinoma samples.  
The LC-MS analysis method has the potential to be transformed into a targeted and 
quantitative method. For this purpose, a wider range of standards would be needed to create a 
calibration curve. There is no need to have a standard for each lipid species targeted with the 
method, as phospholipids within the same class have linear ionization responses [182]. 
Measuring between five and six phospholipids per class with different carbon chain lengths in 
different concentrations would make it possible to calculate the ionization response within each 
class. Based on this principle it would be possible to create a calibration curve not just related 
to the concentration but also related to the fatty acid chain length, as discussed in chapter four. 
As an internal standard, it would be possible to continue to use one or two phospholipids per 
class with odd chain fatty acids as they are not common in the human body.  
To target PA and PG classes, the loss of the fragment 153Da in negative ion mode 
demonstrated insufficient accuracy, as this fragment can be observed in the fragmentation of 
other phospholipids. To extend the LC-MS method for PA and PG classes, the analysis of 
specific lipid species has the potential to allow a more accurate analysis of these two lipid 
classes. MRM transitions based on fragments related to their fatty acid composition would be 
lipid specific and consequently the sensitivity would increase. The only disadvantage of this 
approach is the impossibility of targeting the entire class in one function to be able to do a first 
screening and identify the lipid species to target.  
During the literature research of lipid metabolism in cancer, the LPAAT enzyme was 
demonstrated to have a crucial role in PA synthesis, and consequently mTOR related pathways 
[192]. As such, the analysis of this enzyme by immunohistochemistry could give new insights 
into the two pathways for PA synthesis recognised to be altered in cancer.  
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In conclusion, DESI-MS is capable of spatially characterising the different tissue types 
based on their molecular phenotypes, perfectly matching their histology. Moreover, this 
technique is also capable of differentiating tumour types and malignancies in ovarian cancer. 
The tissue molecular map obtained by DESI-MSI makes this technique ideal to be used as 
diagnostic tool to complement current histology-based techniques as shown for ovarian cancer. 
Furthermore, this molecular information brought us new insights about the systems 
biochemistry. This study brings DESI-MSI one step closer to the application of this technique 
in histology-level cancer diagnostics.  
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Appendix 1 Supplementary Information  
 
Supplementary Table 0.1. Phosphatidylserine (PS) species targeted together with their identification, 
retention time, transition collision energy and cone voltage in positive ion mode. 
m/z Lipid ID RT Transition  
Collision 
energy 
Cone  
voltage 
762.53 PS 34:1 5.50 762.5->577.5 20 20 
788.54 PS 36:2 5.70 788.5->603.5 20 20 
790.56 PS 36:1 6.30 790.5->605.5 20 20 
812.54 PS 38:4 5.70 812.5->627.5 20 20 
814.56 PS 38:3 5.95 814.5->629.5 20 20 
836.54 PS 40:6 5.60 836.5->651.5 20 20 
838.56 PS 40:5 5.70 838.5->653.5 20 20 
840.57 PS 40:4 6.20 840.5->655.5 20 20 
 
 
Supplementary Table 0.2. Phosphatidylinositol (PI) species targeted together with their 
identification, retention time, transition collision energy and cone voltage in negative ion mode. 
m/z Lipid ID RT Transition  
Collision 
energy 
Cone  
voltage 
833.52 PI 18:2/16:0 3.7 833.5->241 44 40 
835.53 PI 18:1/16:0 4.1 835.5->241 44 40 
861.55 PI 18:2/18:0 4.35 861.5->241 44 40 
863.57 PI 18:0/18:1 4.75 863.6->241 44 40 
883.53 PI 38:5 3.8 883.5->241 44 40 
885.55 PI 18:0/20:4 4.3 885.6->241 44 40 
887.57 PI 18:0/20:3 4.55 887.6->241 44 40 
909.55 PI 40:6 4.18 909.6->241 44 40 
913.58 PI 18:0/22:4 4.75 913.6->241 44 40 
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Supplementary Table 0.3. Lysophosphatidylcholine (LPC) species targeted together with their 
identification, retention time, transition collision energy and cone voltage in positive ion mode. 
m/z Lipid ID RT Transition  
Collision 
energy 
Cone  
voltage 
496.34 LPC 16:0 3.00 496.4->184 28 20 
520.34 LPC 18:2 2.50 520.4->184 28 20 
522.36 LPC 18:1 3.00 522.4->184 28 20 
524.37 LPC 18:0 3.80 524.4->184 28 20 
544.34 LPC 20:4 2.50 544.4->184 28 20 
546.36 LPC 20:3 2.80 546.4->184 28 20 
568.34 LPC 22:6 2.50 568.5->184 28 20 
 
 
Supplementary Table 0.4. Phosphatidylethanolamine (PE) species targeted together with their 
identification, retention time, transition collision energy and cone voltage in positive ion mode. 
m/z Lipid ID RT Transition  
Collision 
energy 
Cone 
voltage 
716.55 PE 18:2/16:0 6.15 716.5->575.5 18 20 
718.54 PE 18:1/16:0 6.60 718.5->577.52 18 20 
744.55 PE 18:1/18:1 6.80 744.6->603.53 18 20 
746.57 PE 18:0/18:1 7.20 746.6->605.55 18 20 
764.52 PE 38:6 5.95 764.5->623.5 18 20 
766.53 PE 38:5 6.10 766.5->625.51 18 20 
768.55 PE 18:0/20:4 6.60 768.6->627.53 18 20 
770.57 PE 38:3 7.00 770.6->629.55 18 20 
772.59 PE 38:2 7.30 772.6->631.5 18 20 
774.60 PE 38:1 7.80 774.6->633.58 18 20 
788.52 PE 40:8 5.60 788.5->647.5 18 20 
790.54 PE 40:7 6.00 790.5->649.51 18 20 
792.55 PE 40:6 6.60 792.6->651.53 18 20 
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Supplementary Table 0.5. Ceramide (Cer) species targeted together with their identification, 
retention time, transition collision energy and cone voltage in positive ion mode. 
m/z Lipid ID RT Transition  
Collision 
energy 
Cone  
voltage 
502.50 Cer d18:1/16:0 8.20 502.5->264 25 20 
604.60 Cer d18:1/22:0 9.50 604.6->264 25 20 
630.62 Cer d18:1/24:1 9.50 630.7->264 25 20 
632.63 Cer d18:1/24:0 9.70 632.7->264 25 20 
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Supplementary Figure 0.1. Integrated area of the internal standard for lipid classes analysed across all QC runs from 
this study. LPC- lysophosphatidylcholine, PI- phosphatidylinositol, PC- phosphatidylcholine, Cer- ceramide, PS- 
phosphatidylserine. 
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Supplementary Figure 0.2. Overlaid chromatograms of all QC runs for Cer, PS, PC and PE classes. Average of 
the ion peak areas integrated for Cer, PS, PC and PE classes in all QC samples analysed across the run Cer- 
ceramide, PS- phosphatidylserine, PC- phosphatidylcholine, PE- phosphatidylethanolamine). 
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Appendix II – Conferences / Awarded travel grants / Publications  
 
 
Oral presentations:  
• Title: Phospholipids and fatty acids in ovarian cancer – how do they behave?  
Precision Medicine conference, London, July 2016 
• Title: DESI-MS and REIMS as Excellent Techniques to Complement and Support Histology in 
Ovarian; MSACL - EU, Salzburg September 2015 
• Title: Systems biology approach for the classification of ovarian cancer specimens by desorption 
electrospray ionization mass spectrometry; 11th Annual International Conference of the 
Metabolomics Society; June 2015; San Francisco, USA 
 
 
Posters:  
• Title: Targeted DESI Mass Spectrometry Imaging in Ovarian Cancer; Authors: Luisa Doria , 
James McKenzie , Anna Mróz , Abigail Speller , Francesca Rosini , David Phelps , Emrys Jones , 
Renata Soares , Kirill Veselkov , Sadaf Ghaem-Maghami , Zoltan Takats ; ASMS 2016 San 
Antonio 
• Title: Phospholipids as potential biomarkers for ovarian cancer: spatial localization and use in 
diagnosis; Authors: Luisa Doria, James McKenzie, Anna Mróz , Abigail Speller, David Phelps, 
Kirill Veselkov, Sadaf Ghaem-Maghami, Zoltan Takats;  MSCL - US, Palms Spring, February 
2016 
➢ Best poster award in MSCL 2016 Palm Spring, USA 
➢ MSACL 2016 US Young Investigator Travel Grant  
• Title: Epithelial ovarian carcinoma analysis by DESI-MS; Authors: Luisa Doria, Sabine 
Guenther, Abigail Speller, Anna Mróz, Kirill Veselkov, Zoltan Takats: ASMS 2015; St Louis  
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Publications:  
• Title: Epithelial ovarian carcinoma diagnosis by desorption electrospray ionization mass 
spectrometry imaging. Authors: Maria Luisa Dória, James S. McKenzie, Anna Mróz, David L. 
Phelps, Abigail Speller, Francesca Rosini, Nicole Strittmatter, Ottmar Golf, Kirill Veselkov, Robert 
Brown, Sadaf Ghaem-Maghami & Zoltan Takats; Journal: Sci Rep December 2016; 6: 39219. 
DOI: 10.1038/srep39219 
 
• Title: Shotgun Lipidomic Profiling of the NCI60 Cell Line Panel Using Rapid Evaporative 
Ionization Mass Spectrometry; Authors: Nicole Strittmatter, Anna Lovrics, Judit Sessler, James S. 
McKenzie, Zsolt Bodai, M. Luisa Doria, Nora Kucsma, Gergely Szakacs, and Zoltan Takats; 
Journal: Anal. Chem., July 2016, 88 (15), pp 7507–7514; DOI: 10.1021/acs.analchem.6b00187 
 
• Title: Desorption electrospray ionization for targeted mass spectrometry imaging; Authors: 
Andreas Dannhorn, Maria Luisa Doria, James McKenzie,  Emrys Jones,  Renata Soares, Anna 
Mróz, Jocelyn Tillner, John G. Swales, Richard J.A. Goodwin, Sadaf Ghaem-Maghami, Zoltan 
Takats; Journal: Chem. Comm., in preparation  
 
 
